 Patent Application Title |
Patent App Num. |
Date |
 Herbal composition for preventing and/or treating anxiety related conditions | 20130149370 | 20130613 |  The present invention relates to herbal compositions for the treatment and/or prevention of anxiety disorders or stress. These compositions comprise hawthorn fruit (Shan Zha), light wheat grain (Fu xiao mai) and Lilly Bulb (bai hi) in amounts which are effective to treat anxiety conditions. The compositions may further comprise Chinese date (Da zao).
... | | Syringe apparatus | 20130149664 | 20130613 |  The present invention is designed to prevent or reduce anxiety in child or adolescent patients undergoing dental or medical procedures through a design to conceal or hide elements of a traditional syringe. The use of an opaque sleeve or exterior surface shaped in a manner other than a tube is used to conceal the interior of the syringe barrel, mask the plunger, and partially obstruct the view of the cannula assembly.
... | | Piperidinyl pyrimidine amides as kv7 potassium channel openers | 20130150391 | 20130613 |  The present invention relates to compounds of Formula (I) as described herein or a pharmaceutically acceptable salt thereof, pharmaceutical composition comprising a compound of Formula (I) or a pharmaceutically acceptable salt thereof and methods of treating, or manufacture of a medicament to treat, a disease, disorder, or condition of the central nervous system, including bipolar disorder, depressive disorders, anxiety disorders, cognitive disorders, pain disorders, urogentital disorder, and epilepsy, among the other diseases, disorders or conditions discussed herein as mono-therapy or in combination with another active pharmaceutical ingredient.
... | | S-adenosylmethionine formulations with enhanced bioavailability | 20130142847 | 20130606 |  Provided herein are compositions and methods to enhance the absorption of S-adenosylmethionine (SAMe) and methods of treating various disorders or diseases using non-parenteral SAMe formulations with enhanced-absorption and improved bioavailability. In certain embodiments, the enhanced bioavailability formulations provided herein may be used to treat a variety of diseases or disorders, such as for example, psychiatric disorders including, generalized anxiety disorder, obsessive compulsive disorder, post traumatic stress disorder, panic disorder, depressive disorders (e.g. major clinical depression) and dysthymia; as well as treating liver disorders, cancer, autoimmune disorders, inflammatory disorders, joint disorders, gastrointestinal disorders and cardiovascular disease.
... | | Medical food for the dietary management of depression and anxiety and methods thereof | 20130142883 | 20130606 |  A medical food for the dietary management of depression and/or anxiety includes water containing from 0.0002 to 0.0278 mol. % of isotopologue HOD, preferably, from 0.0178 to 0.0278 mol. % of isotopologue HOD. Further, a method for the dietary management of depression and/or anxiety uses the step of administering to a subject in need thereof the medical food. Further, a method of the treatment of depression includes the steps of administering to a subject an antidepressant drug and administering to the subject the medical food. Further, a method of the treatment of anxiety includes the steps of administering to a subject an antianxiety drug and administering to the subject the medical food.
... | Subscribe to updates on this page: Anxiety RSS  | | Ultrasound neuromodulation treatment of anxiety (including panic attacks) and obsessive-compulsive disorder | 20130144192 | 20130606 | | Disclosed are methods and systems and methods for non-invasive neuromodulation using ultrasound to treat anxiety (including panic attacks) and Obsessive-Compulsive Disorder. The neuromodulation can produce acute or long-term effects. The latter occur through Long-Term Depression (LTD) and Long-Term Potentiation (LTP) via training. Included is control of direction of the energy emission, intensity, frequency, pulse duration, and phase/intensity relationships to targeting and accomplishing up regulation and/or down regulation.
... | | Heteroaryl-pyrazole derivative | 20130137865 | 20130530 | | A compound represented by formula [I] and a pharmaceutically accepted salt of said compound are a novel compound and a pharmaceutically accepted salt thereof which exert antagonistic activity against group II metabotropic glutamate (mGlu) receptors, and are effective as a novel preventive or therapeutic agent for disorders such as mood disorders (depressive disorder, bipolar disorder, etc.), anxiety disorders (generalized anxiety disorder, panic disorder, obsessive-compulsive disorder, social anxiety disorder, posttraumatic stress disorder, a specific phobic disorder, acute stress disorder, etc.), schizophrenia, Alzheimer's disease, cognitive impairment, dementia, drug dependence, convulsions, shivering, pain, sleep disorders, and the like.
... | | System and method for reorienting and decreasing patient anxiety in a medical facility | 20130131439 | 20130523 | | A computer system for reorienting, reducing anxiety, and/or reducing delirium risk of a patient in a hospital is provided. The computer has a central processing unit (CPU) for executing machine instructions for a passive and active module and a memory for storing the machine instructions. The machine instructions implement functions when executed by the CPU. Patient-specific content is inputted into the CPU. The system then communicates the patient-specific content from the CPU to the patient by displaying and looping the patient-specific content such that any point of the loop of the patient-specific content helps reorient and reduce anxiety and delirium risk.
... | | Ethinyl-pyrazole derivative | 20130123500 | 20130516 | | Provided is a novel compound represented by formula [I] or a pharmaceutically acceptable salt thereof having antagonistic activity against group II metabolism-type glutamic acid (m-Glu) receptors. The compound or pharmaceutically acceptable salt thereof is useful as a prophylactic or therapeutic agent for diseases such as new mood disorders (depressive and bipolar disorders), anxiety disorders (generalized anxiety disorder, panic disorder, obsessive-compulsive disorder, social anxiety disorder, post-traumatic stress disorder, specific phobias, and acute stress disorder), schizophrenia, Alzheimer's disease, cognitive dysfunction, dementia, drug dependence, convulsions, tremors, pain, sleep disorders, and the like.
... | | Indolealkylamino-withasteroid conjugates and method of use | 20130115316 | 20130509 | | A group of indolealkylamino-withasteroid conjugates, isolated and purified from Withania somnifera, are described. A synthetic method of making an indolealkylamino-withasteroid compound is provided. In vitro acetyl cholinesterase inhibitory activity and methods for treatment of dementia and dementia-related disorders, such as Alzheimer's disease, and anxiety and depressive disorders in mammals are demonstrated with these novel compositions.
... | | High protein supplement | 20130108731 | 20130502 | | The present disclosure relates to high protein dietary supplements for treating various symptoms and diseases associated with protein deficiency including weight gain, obesity, catabolic diseases, fibromyalgia, anxiety reactions, posttraumatic stress and chronic fatigue syndrome. Embodiments of dietary supplements comprise combinations of proteins, essential and semi-essential amino acids including L-Lysine, L-Arginine, and/or L-Histidine.
... | | Polymorphic forms of 1-[4-(5-cyanoindol-3-yl)butyl]-4-(2-carbamoylbenzofuran-5-yl)piperazine hydrochloride | 20130102616 | 20130425 | | The invention relates to new crystalline modifications of the hydrochloride of 1-[4-(5-cyanoindol-3-yl)butyl]-4-(2-carbamoyl-benzofuran-5-yl)-piperazine, crystalline modification of the dihydrochloride of 1-[4-(5-cyanoindol-3-yl)butyl]-4-(2-carbamoyl-benzofuran-5-yl)-piperazine and amorphous 1-[4-(5-cyanoindol-3-yl)butyl]-4-(2-carbamoyl-benzofuran-5-yl)-piperazine hydrochloride which are suitable in particular for the preparation of solid medicaments for the treatment or prevention of depressive disorders, anxiety disorders, bipolar disorders, mania, dementia, substance-related disorders, sexual dysfunctions, eating disorders, obesity, fibromyalgia, sleeping disorders, psychiatric disorders, cerebral infarct, tension, for the therapy of side-effects in the treatment of hypogonadism, secondary amenorrhea, premenstrual syndrome and undesired puerperal lactation.
... | | System and method for reorienting and decreasing patient anxiety in a medical facility | 20130102836 | 20130425 | | A computer system for reorienting, reducing anxiety, and/or reducing delirium risk of a patient in a hospital is provided. The computer has a central processing unit (CPU) for executing machine instructions for a passive and active module and a memory for storing the machine instructions. The machine instructions implement functions when executed by the CPU. Patient-specific content is inputted into the CPU. The system then communicates the patient-specific content from the CPU to the patient by displaying and looping the patient-specific content such that any point of the loop of the patient-specific content helps reorient and reduce anxiety and delirium risk.
... | Subscribe to updates on this page: Anxiety RSS | | Heterocyclic compounds for the treatment of neurological and psychological disorders | 20130096089 | 20130418 | | Lactam compounds of Formula I and their use for the treatment of neurological and psychiatric disorders including schizophrenia, bipolar disorder, anxiety disorder and insomnia is disclosed.
... | | Kennel with automatically opening door | 20130068172 | 20130321 | | The present invention seeks to prevent damage to property resulting from an animal's separation anxiety which occurs when a pet owner departs, while minimizing the period of time the dog is confined. The device incorporates an automatically releasing door of a kennel or leash. For instance, the owner of a canine can place the dog in a kennel prior to leaving his or her residence. The owner can initiate a timer on the kennel or leash, and the kennel door opens or leash releases after a pre-determined amount of time, such as 30 minutes.
... |
| Anxioytic marcgraviaceae compositions containing betulinic acid, betulinic acid derivatives, and methods | 20130065868 | 20130314 | | Pharmaceutical compositions for preventing or treating anxiety, comprising betulinic acid or derivatives thereof are provided. Methods for preventing or treating anxiety with betulinic acid or derivatives thereof are also provided. The invention further provides betulinic-acid containing preparations of plants of the family Marcgraviaceae having anxiolytic activity and methods for making such extracts and using them to prevent or treat anxiety in a subject.
... | | Combinations of eszopiclone and trans 4-(3,4-dichlorophenyl)-1,2,3,4-tetrahydro-n-methyl-1-napthalenamine or trans 4-(3,4-dichlorophenyl)-1,2,3,4-tetrahydro-1-napthalenamine, and methods of treatment of menopause and mood, anxiety, and cognitive disorders | 20130065904 | 20130314 | | One aspect of the present invention relates to pharmaceutical compositions containing two or more active agents that when taken together can be used to treat, e.g., menopause, mood disorders, anxiety disorders, or cognitive disorders. The first component of the pharmaceutical composition is a sedative eszopiclone. The second component of the pharmaceutical composition is trans 4-(3,4-dichlorophenyl)-1,2,3,4-tetrahydro-N-methyl-1-napthalenamine or trans 4-(3,4-dichlorophenyl)-1,2,3,4-tetrahydro-1-napthalenamine. The present invention also relates to a method of treating menopause, perimenopause, mood disorders, anxiety disorders, and cognitive disorders.
... | | Treatment of inflammatory skin disease and psychiatric conditions | 20130039921 | 20130214 | | The number of acne lesions in a human subject is reduced by administering to the subject a pharmaceutical composition that includes a pharmaceutically acceptable carrier and a therapeutically effective amount of an agent that selectively binds IL-1α. Anxiety and other psychiatric conditions are also improved with this treatment.
... | | Pharmaceutical compositions for treating depression and anxiety | 20130040903 | 20130214 | | Pharmaceutical compositions or functional foods for treating depression and anxiety comprising ginseng saponin (Rgl+Rbl), glycyrrhizic acid and jujuba cAMP. Experiments demonstrate that as compared with the preferred drug for treating depression and anxiety paroxetine and diazepam in the art, the present invention has significant anti-depression and anxielytic efficacy.
... | | Method of treating binge eating disorder | 20130028842 | 20130131 | | The invention provides methods of treating binge eating disorders, obesity resulting from binge eating behavior, and depression. The invention includes methods of treating certain co-morbidities in ADHD and ADD patients; for example the invention includes methods of treating generalized anxiety disorder, obsessional and ruminative thought disorders, and obsessive/compulsive behavior in ADHD and ADD patients. The invention also includes combination methods of treatment in which an amphetamine prodrug, methylphenidate prodrug, or methylphenidate analog is administered with one or more other active agents. Packaged pharmaceutical compositions containing an amphetamine or methylphenidate prodrug, instructions for using the pro drug to treat certain disorders, and optionally one or more other active agents are provided by the invention.
... | | Pomegranate extract having a high ellagic acid content, and use of the pomegranate extract | 20130028994 | 20130131 | | A pomegranate pulp extract is disclosed. The pomegranate pulp extract is effective in relieving women's menopausal symptoms, anxiety disorders, depression or attention deficit disorders due to the presence of a large amount of ellagic acid. Further disclosed is a method for further improving the relieving effect of the pomegranate extract on women's menopausal symptoms, anxiety disorders, depression or attention deficit disorders. The method includes increasing the content of ellagic acid in the pomegranate extract.
... | | Dog anxiety relief bone conduction audio device, system | 20130030242 | 20130131 | | A waterproof audio device and system that transmits sound via transcutaneous bone conduction provides therapeutic auditory stimulation music to a dog. The device is integrated into an adjustable dog collar component and a removable adjustable muzzle component. Both the dog collar and the muzzle components will be adjustable or available in various sizes to fit any sized dog. The present invention uses commercially available transducers to produce sounds in the low, mid and high frequency ranges. A commercially available sound source for the therapeutic auditory stimulation music signal can also be provided as part of the waterproof audio device. Commercially available fasteners enable the dog's owner to position the device on the neck and head of the dog for providing acceptable sound conduction and individualized fit... | | Amniotic fluid collector | 20130030325 | 20130131 | | According to the present invention, an amniotic fluid collector is configured so as to be inserted and positioned inside the vagina of a birthing mother in order to collect amniotic fluid from the womb of the birthing mother. In particular, the amniotic fluid collector of the present invention comprises: a receiving member, in the side of which an opening is defined, which is inserted into the vagina of the birthing mother and which has a receptacle defined therein for receiving the amniotic fluid; and a positioning portion for positioning the receiving member inside the vagina. Thus, the effects of alleviating pain and psychological anxiety of a birthing mother and eliminating the danger of the occurrence of complications can be achieved, as well as those of easily... | | Nk1 antagonists | 20130023503 | 20130124 | | wherein Ar1 and Ar2 are optionally substituted phenyl or heteroaryl, X1 is an ether, thio or imino linkage, R4 and R5 are not both H or alkyl, and the remaining variables are as defined in the specification, useful for treating a number of disorders, including emesis, depression, anxiety and cough. Pharmaceutical compositions. Methods of treatment and combinations with other agents are also disclosed.
... | | Tactile user devices and methods | 20130023722 | 20130124 | | A patient seeking complementary and alternative medicine must visit a practitioner which is not always convenient or possible. It would be beneficial to provide a patient with a simple means of deriving benefit from such physical CAM techniques in a non-intimidating manner whereby the means has familiarity associated with it. Even with conventional medicine children, infants, toddlers, and babies require medical treatment and experience fear and/or anxiety arising from visiting the medical practitioner or with the treatment. According to embodiments of the invention provide patients are provided means to exploit CAM techniques away from the practitioner or allow patients to not associate activities with a medical treatment but another activity, such as playing in the instance of a child. Variations of the means allow medical monitoring... | | Receptor modulators exhibiting neuroprotective and memory enhancing activities | 20130012462 | 20130110 | | The present invention provides therapeutically active compounds and compositions as NMDA and MC receptor antagonists, which are useful in preventing and treating central nervous system disorders by inhibiting over-activation of NMDA and/or MC receptors. In one aspect, the present invention provides methods of treating and/or preventing neurodegenerative diseases and neuropathological disorders, methods of providing neuroprotection under stress conditions such as a stroke, methods of enhancing the brain's cognitive functions and methods of treating depression, anxiety and cachexia induced by a chronic disease in mammals and humans.
... | | Novel anxiolytic compounds | 20130012508 | 20130110 | | which may possess useful therapeutic activity in a range of central nervous system disorders, and in particular, anxiety disorders.
... | | Novel anxiolytic compounds | 20130012509 | 20130110 | | which may possess useful therapeutic activity in a range of central nervous system disorders, and in particular, anxiety disorders.
... | | 2-azetidinemethaneamines and 2-pyrrolidinemethaneamines as taar-ligands | 20130005988 | 20130103 | | R1, R2, R3, Ar, n and o are as defined herein and to their pharmaceutically acceptable active salts. Compounds of formula I have a good affinity to the trace amine associated receptors (TAARs), especially for TAAR1 and are useful for the treatment of depression, anxiety disorders, bipolar disorder, attention deficit hyperactivity disorder (ADHD), stress-related disorders, psychotic disorders such as schizophrenia, neurological diseases such as Parkinson's disease, neurodegenerative disorders such as Alzheimer's disease, epilepsy, migraine, hypertension, substance abuse and metabolic disorders such as eating disorders, diabetes, diabetic complications, obesity, dyslipidemia, disorders of energy consumption and assimilation, disorders and malfunction of body temperature homeostasis, disorders of sleep and circadian rhythm, and cardiovascular disorders.
... | | Method for identifying increased risk of anxiety disorders | 20120322068 | 20121220 | | The present invention is for methods for identifying a human having an increased risk for anxiety disorders. The method involves genotyping the human for a specific brain-derived neurotrophic factor (BDNF) single nucleotide polymorphism (SNP), and/or administering a fear conditioning procedure while measuring fear, and administering an extinction procedure while measuring fear. The method can also involve comparing/MRI images of the amygdala of the human acquired during conditioning and extinction and determining if the human is unresponsive to extinction therapy by noting heightened and non-declining activity in the amygdala during extinction.
... | | Heterocyclic compounds for the treatment of neurological and psychological disorders | 20110015156 | 20110120 | | Lactam compounds of Formula I and their use for the treatment of neurological and psychiatric disorders including schizophrenia, bipolar disorder, anxiety disorder and insomnia is disclosed.
... | | Method of enhancing a participant's performance in a sporting activity | 20110014991 | 20110120 | | According to one aspect of the present invention, a method of improving a participant's ability to move an object toward a desired target through athletic movement is provided. The method comprises establishing a point of focus that is positioned outward from a participant's body. The method further comprises instructing the participant to continuously move the point of focus through one or more series of bodily movements within the field of vision of the participant. By shifting his or her emphasis on continuously moving the point of focus, the participant is able to improve focus and concentration, and eliminate the stress and anxiety associated with executing an athletic movement. The method also naturally triggers correct body mechanics, including the proper sequential release of the participant's joints.
... | | Alpha-aminoamide derivatives useful in the treatment of psychiatric disorders | 20110014304 | 20110120 | | The disclosure relates to pharmacotherapy of a psychiatric disorder which is schizophrenia and/or anxiety, wherein schizophrenia includes schizophrenia related disorders such as brief psychotic disorders, delusional disorders, schizoaffective disorders, and schizophreniform disorders, and anxiety includes panic disorders, obsessive-compulsive disorders (OCD), post-traumatic stress disorders (PTSD), social phobia or social anxiety disorders, specific phobia, and generalized anxiety disorders (GAD). The compounds of the disclosure are useful for the treatment of the above psychiatric disorders alone or in combination with other therapeutical agents effective in the treatment of schizophrenia and/or anxiety disorders.
... | | Smoking cessation with body weight maintenance and nutritional supplement | 20110014277 | 20110120 | | Disclosed is a compound and methods for use by an individual attempting to reduce or cease tobacco smoking or one exposed to environmental tobacco smoke. The compound includes a first component blocking nicotine receptor sites to reduce nicotine cravings or withdrawal symptoms, a second component increasing serotonin levels and acting synergistically with the first component to reduce nicotine cravings or withdrawal symptoms, assisting in maintaining body weight and reducing increased stress and anxiety, and a third component acting synergistically with the first and/or second component to reduce nicotine cravings or withdrawal symptoms, maintain body weight, and/or reduce increased stress and anxiety. The third component comprises a supplement that replenishes depleted body substance(s), repairs damaged body substance(s), and/or ameliorates the impaired function of body substance(s). Some combination... | | Imidazo[1,2-a]pyridine derivatives and their use as positive allosteric modulators of mglur2 receptors | 20110009441 | 20110113 | | The present invention relates to novel compounds, in particular novel imidazo[1,2-a]piridine derivatives according to Formula (I). The compounds according to the invention are positive allosteric modulators of metabotropic receptors-sub-type 2 (‘mGluR2’) which are useful for the treatment or prevention of neurological and psychiatric disorders associated with glutamate dysfunction and diseases in which the mGluR2 subtype of metabotropic receptors is involved. In particular, such diseases are central nervous system disorders selected from the group of anxiety, schizophrenia, migraine, depression, and epilepsy. The invention is also directed to pharmaceutical compositions and processes to prepare such compounds and compositions, as well as to the use of such compounds for the prevention and treatment of such diseases in which mGluR2 is involved.
... | | Pyrid-2yl fused heterocyclic compounds, and compositions and uses thereof | 20110009432 | 20110113 | | where R1, R2, and R3 are as defined herein. Provided compounds and pharmaceutical compositions thereof are useful for the prevention and treatment of a variety of conditions in mammals including humans, including by way of non-limiting example, pain, inflammation, cognitive disorders, anxiety, depression, and others.
... | | Phenyl-piperazine derivatives as serotonin reuptake inhibitors | 20110009423 | 20110113 | | wherein the substituents are defined in the application. The compounds are useful in the treatment of an affective disorder, including depression, anxiety disorders including general anxiety disorder and panic disorder and obsessive compulsive disorder.
... | | Cyclic triazo and diazo sodium channel blockers | 20110009413 | 20110113 | | Compounds of general structure in which X and Y are each N or C with at least one of X and Y being N; Z is a single bond or an optionally substituted linking group R1 is hydrogen or a substituent group; R2 is amino or a substituent group; N* is amino when RI is hydrogen or ═NH when R1 is a substituent group; or N* is a group NRaRb where Ra and Rb are independently H or an alkyl group; or N* is an optionally substituted piperazinyl ring; and A is an optionally substituted heterocyclic or carbocyclic ring system which may be linked to the triazo/diazo ring through R2 to form a fused multicyclic ring; are indicated as suitable for treatment of disorders in mammals... | | Azinone-substituted azepino[b]indole and pyrido-pyrrolo-azepine mch-1 antagonists, methods of making, and use thereof | 20110003793 | 20110106 | | Novel MCH-1 receptor antagonists are disclosed. These compounds are used in the treatment of various disorders, including obesity, anxiety, depression, non-alcoholic fatty liver disease, and psychiatric disorders. Methods of making these compounds are also described in the present invention.
... | | Non-basic melanin concentrating hormone receptor-1 antagonists and methods | 20110003759 | 20110106 | | Additionally, the present application provides pharmaceutical compositions containing at least one compound according to Formula I and optionally at least one additional therapeutic agent. Finally, the present application provides methods for treating a patient suffering from an MCHR-1 modulated disease or disorder such as, for example, obesity, diabetes, depression or anxiety by administration of a therapeutically effective dose of a compound according to Formula I.
... | | Azinone-substituted azabicycloalkane-indole and azabicycloalkane-pyrrolo-pyridine mch-1 antagonists, methods of making, and use thereof | 20110003739 | 20110106 | | Novel MCH-1 receptor antagonists are disclosed. These compounds are used in the treatment of various disorders, including obesity, anxiety, depression, non-alcoholic fatty liver disease, and psychiatric disorders. Methods of making these compounds are also described in the present invention.
... | | Azinone-substituted azapolycycle mch-1 antagonists, methods of making, and use thereof | 20110003738 | 20110106 | | Novel MCH-1 receptor antagonists are disclosed. These compounds are used in the treatment of various disorders, including obesity, anxiety, depression, non-alcoholic fatty liver disease, and psychiatric disorders. Methods of making these compounds are also described in the present invention.
... | | Azabicycloalkane-indole and azabicycloalkane-pyrrolo-pyridine mch-1 antagonists, methods of making, and use thereof | 20110003737 | 20110106 | | Novel MCH-1 receptor antagonists are disclosed. These compounds are used in the treatment of various disorders, including obesity, anxiety, depression, non-alcoholic fatty liver disease, and psychiatric disorders. Methods of making these compounds are also described in the present invention.
... | | Therapeutic agents useful for treating pain | 20100331369 | 20101230 | | where Ar1, Ar2, X, R3, and m are as disclosed herein or a pharmaceutically acceptable salt thereof (a “Cycloheteroalkenyl Compound”); compositions comprising an effective amount of a Cycloheteroalkenyl Compound; and methods for treating or preventing pain, UI, an ulcer, IBD, IBS, an addictive disorder, Parkinson's disease, parkinsonism, anxiety, epilepsy, stroke, a seizure, a pruritic condition, psychosis, a cognitive disorder, a memory deficit, restricted brain function, Huntington's chorea, amyotrophic lateral sclerosis, dementia, retinopathy, a muscle spasm, a migraine, vomiting, dyskinesia, or depression in an animal comprising administering to an animal in need thereof an effective amount of a Cycloheteroalkenyl Compound are disclosed herein.
... | | Connecting portion for boarding bridge and boarding bridge | 20100325818 | 20101230 | | It is provided a connecting portion for a boarding bridge that eliminates the level difference between the doorway portion of the aircraft and the passage, reduces the anxiety of the passengers, and can be raised and lowered smoothly. A passage (27) is formed by a stationary passage (29) and an alignment passage (31) that is arranged at the distal end portion of the stationary passage (29) and adjusts the level difference between the stationary passage (29) and the doorway portion (23); the alignment passage (31) includes an elevating floor (35), on the stationary passage (29) side, having a pivot shafts (41) that is substantially perpendicular to the passenger traffic direction (T) and pivots centered on the pivot shafts (41), and an alignment floor (37), at the... | | Av system with skin care and health care functions | 20100324624 | 20101223 | | This specification discloses an AV system with the skin care and health care functions. An AV system and a pulse current generator are integrated. A conductor transmits a pulse current output from the pulse current generator to a human body. The pulse current cures or alleviates the user in pain, melancholy, anxiety, and insomnia, accelerates the recovery of wound or bone, and reduces the side effects of radiotherapy and chemotherapy.
... | | Substituted imidazopyridine derivatives as melanocortin-4 receptor antagonists | 20100324036 | 20101223 | | The present invention relates to substituted imidazopyridine derivatives as melanocortin-4 receptor (MC-4R) modulators, in particular as melanocortin 4 receptor antagonists. The antagonists are useful for the treatment of disorders and diseases such as cachexia induced by e.g. cancer, chronic kidney disease (CKD) or chronic heart failure (CHF), muscle wasting, anorexia induced by e.g. chemotherapy or radiotherapy, anorexia nervosa, amyotrophic lateral sclerosis (ALS), pain, neuropathic pain, anxiety and depression.
... | | Pressure-applying garment for animals | 20100319632 | 20101223 | | A garment to reduce an animal's anxiety, fearfulness, overexcitement, or a combination thereof. The garment may include a central portion, flaps extending from opposite sides of the central portion, and, in some cases, a cinching member that extends from a central area of the central portion. The flaps may be fastened together around the chest and stomach of the animal, and the cinching member may be fastened to the central portion or one or more flaps to tighten the garment further, applying pressure to reduce anxiety, fearfulness, or over-excitement. Straps may be provided to secure the garment to the animal's neck. One material that may be used in making the garment is a fabric made of 55% cotton, 35% polyester, and 10% spandex. The animal may... | | Fused heterocyclic compounds, and compositions and uses thereof | 20100317676 | 20101216 | | where A, B, L, N, R1, R3, R4′, Y and Z are as defined herein. The compounds and pharmaceutical compositions thereof are useful for the prevention and treatment of a variety of conditions in mammals including humans, including by way of non-limiting example, pain, inflammation, cognitive disorders, anxiety, depression, and others.
... | | 2-aminooxazolines as taar1 ligands | 20100311798 | 20101209 | | R1, R2, R2′, X, Y, andn are as defined in the specification or to a pharmaceutically suitable acid addition salt thereof. The compounds of formula I are active on the TAAR1 receptor and are therefore suitable for the treatment of depression, anxiety disorders, bipolar disorder, attention deficit hyperactivity disorder, stress-related disorders, psychotic disorders, schizophrenia, neurological diseases, Parkinson's disease, neurodegenerative disorders, Alzheimer's disease, epilepsy, migraine, substance abuse and metabolic disorders, eating disorders, diabetes, diabetic complications, obesity, dyslipidemia, disorders of energy consumption and assimilation, disorders and malfunction of body temperature homeostasis, disorders of sleep and circadian rhythm, and cardiovascular disorders.
... | | 3-substituted propanamine compounds | 20100311789 | 20101209 | | or a pharmaceutically acceptable salt thereof are disclosed. Pharmaceutical compositions containing the subject compounds are also disclosed. The subject compounds are useful for the treatment of diseases of the central nervous system, such as depression, anxiety and pain disorders.
... | | Intranasal carbetocin formulations and methods for the treatment of autism | 20100311655 | 20101209 | | Methods and compositions containing oxytocin or an oxytocin analog, such as carbetocin, are provided for the prevention and treatment of autism spectrum disorders, related disorders and symptoms of such disorders. The methods and compositions of this disclosure are effective in the treatment of social withdrawal, eye contact avoidance, repetitive behaviors, anxiety, attention deficit, hyperactivity, depression, loss of speech, verbal communication difficulties, aversion to touch, visual difficulties, comprehension difficulties, and sound and light sensitivity. Additional compositions and methods are provided which employ oxytocin or an oxytocin analog in combination with a secondary or adjunctive therapeutic agent to yield more effective treatment tools against autism spectrum disorders and related disorders.
... | | Pharmaceutical compositions for treating anxiety | 20100310682 | 20101209 | | Pharmaceutical compositions or functional foods for treating anxiety comprising ginseng saponin (Rg1+Rb1), glycyrrhizic acid and jujuba cAMP. Experiments demonstrate that as compared with the preferred drug for treating diazepam in the art, the present invention has significant anxielytic efficacy.
... | | Pharmaceutical compositions for treating depression and anxiety | 20100310683 | 20101209 | | Pharmaceutical compositions or functional foods for treating depression and anxiety comprising ginseng saponin (Rg1+Rb1), glycyrrhizic acid and jujuba cAMP. Experiments demonstrate that as compared with the preferred drug for treating depression and anxiety paroxetine and diazepam in the art, the present invention has significant anti-depression and anxielytic efficacy.
... | | Process for the synthesis of (+) and (-)-1-(3,4-dichlorophenyl)-3-azabicyclo[3.1.0]hexane | 20100298574 | 20101125 | | The present invention is concerned with novel processes for the preparation of (+)-1-(3,4-dichlorophenyl)-3-azabicyclo[3.1.0]hexane or a pharmaceutically acceptable salt thereof, and (−)-1-(3,4-dichlorophenyl)-3-azabicyclo[3.1.0]hexane or a pharmaceutically acceptable salt thereof. These compounds have pharmaceutical utility and are known to be useful for treating e.g., depression, anxiety disorders, eating disorders and urinary incontinence.
... | | Pyrazolopyrimidine derivatives having biological activity on serotonin receptor 5-ht2c | 20100298563 | 20101125 | | The present invention relates to a novel medicinal use of pyrazolopyrimidine compounds having superior effect as serotonin 5-HT2C receptor ligand thus being useful for the prevention and treatment of central nervous system (CNS) diseases. Accordingly, the pharmaceutical composition comprising pyrazolopyrimidine compounds and their pharmaceutically acceptable salts as active ingredients are useful for the prevention and treatment of serotonin 5-HT2C-related central nervous system diseases such as obesity, depression, anxiety and withdrawal symptoms due to drug abuse.
... | | 2-amino-bicyclo(3.1.0) hexane-2, 6-dicarboxylic ester derivative | 20100298561 | 20101125 | | [wherein R1 and R2 are identical or different, and each represents a hydrogen atom, a C1-10alkyl group or the like; X represents a hydrogen atom or a fluorine atom; Y represents —OCHR3R4 or the like (wherein R3 and R4 are identical or different, and each represents a hydrogen atom, a C1-10alkyl group or the like; and n represents integer 1 or 2)], a pharmaceutically acceptable salt thereof or a hydrate thereof.
... | | Pharmaceutical compositions of 5-hydroxytryptophan and serotonin-enhancing compound | 20100298379 | 20101125 | | This invention relates to novel pharmaceutical compositions comprising a therapeutically effective amount of a slow-release formulation of 5-hydroxytryptophan (5-HTP) and a serotonin-enhancing compound. The pharmaceutical compositions for use according to the invention are contemplated particularly useful for combating CNS disorders, including depressive disorders, bipolar disorders, anxiety disorders, obesity and pain.
... | | Tizanidine for the treatment of post-traumatic stress disorder and nightmares | 20100298305 | 20101125 | | Disclosed herein are methods of treating a psychiatric disorder, such as a sleep disorder, an anxiety disorder, a mood disorder or a perceptual disturbance. In one example, a method of treating a sleep disorder or anxiety disorder includes selecting a subject with a sleep disturbance or anxiety disorder in the absence of an underlying physical disorder and administering a therapeutically effective amount of tizanidine, thereby reducing or inhibiting a symptom of the sleep disorder or anxiety disorder. In another example, a method of treating a mood disorder or a perceptual disturbance is disclosed. This method includes selecting a subject with a mood disorder or perceptual disturbance and administering a therapeutically effective amount of tizanidine, thereby reducing or inhibiting a symptom of the mood disorder or perceptual... | | Wireless lan communication device and beacon transmitting method | 20100296495 | 20101125 | | A wireless LAN communication device is provided for making it possible to set beacons including DTIM information elements not to be synchronous in the case that the timing for generating the beacons including DTIM information elements is the same among access points, so that it is avoidable that only a terminal device under a specific access point among access points using the same channel is subjected to a delay and jitters, while anxiety about mutual interference of the terminal devices is removed in the case of broadcast and multicast service, so that a fair broadcast and multicast service can be received. In the device, a wireless LAN control unit (202) detects beacons of other stations received in a prescribed period of time before the transmission of... | | Indazolyl derivatives useful as potassium channel modulating agents | 20090325989 | 20091231 | | Moreover the invention is directed to pharmaceutical compositions useful for the treatment or alleviation of diseases or disorders associated with the activity of potassium channels, in particular respiratory diseases, epilepsy, convulsions, seizures, absence seizures, vascular spasms, coronary artery spasms, renal disorders, polycystic kidney disease, bladder spasms, urinary incontinence, bladder outflow obstruction, erectile dysfunction, gastrointestinal dysfunction, secretory diarrhoea, ischaemia, cerebral ischaemia, ischaemic heart disease, angina pectoris, coronary heart disease, autism, ataxia, traumatic brain injury, Parkinson's disease, bipolar disorder, psychosis, schizophrenia, anxiety, depression, mania, mood disorders, dementia, memory and attention deficits, Alzheimer's disease, amyotrophic lateral sclerosis (ALS), dysmenorrhea, narcolepsy, Reynaud's disease, intermittent claudication, Sjorgren's syndrome, arrhythmia, hypertension, myotonic muscle dystrophia, spasticity, xerostomi, diabetes type II, hyperinsulinemia, premature labour, baldness, cancer, irritable bowel syndrome, immune suppression, migraine and pain.
... | | Piperazine metabotropic glutamate receptor 5 (mglur5) negative allosteric modulators for anxiety/depression | 20090325964 | 20091231 | | wherein the constituent variables are as defined herein. The present teachings further relate to methods for the preparation of the compounds, and to methods for using the compounds for treatment of diseases and disorders including schizophrenia, paranoia, depression, manic-depressive illness and anxiety.
... | | Synthetic resin bottle | 20090321385 | 20091231 | | In a synthetic resin square bottle comprising a body formed by multiple panel walls disposed on the body in a circumferential direction, and a waist portion made of a peripheral groove dented at a roughly middle height position of the body so as to divide each panel wall into an upper panel and a lower panel, recessed areas for fingerhold use are formed in at least a pair of opposing panel walls in a certain area ranging from the waist portion to an upper end portion of the lower panel of each panel wall, and a pair of side ribs is formed on right and left sides of, and in the vicinity of, each recessed area in the lower panel.
... | | Crystalline form of (2s)-(-)-n-(6-chloro-2,3-dihydro-benzo[1,4]dioxin-2-ylmethyl)-sulfamide | 20090318544 | 20091224 | | The present invention is directed to a novel crystalline form of (2S)-(−)-N-(6-chloro-2,3-dihydro-benzo[1,4]dioxin-2-ylmethyl)-sulfamide, pharmaceutical compositions containing said crystalline form and the use of said crystalline form in the treatment of anxiety and related disorders; bipolar depression and mania; depression; epilepsy and related disorders; epileptogenesis; glucose related disorders; lipid related disorders; migraine; obesity; pain; substance abuse; or for neuroprotection. The present invention is further directed to a process for the preparation of the novel crystalline form.
... | | Use of gal3 receptor antagonists for the treatment of depression and/or anxiety and compounds useful in such methods | 20090318504 | 20091224 | | This invention is directed to pyrimidine and indolone derivatives which are selective antagonists for the GAL3 receptor. The invention provides a pharmaceutical composition comprising a therapeutically effective amount of a compound of the invention and a pharmaceutically acceptable carrier. This invention also provides a pharmaceutical composition made by combining a therapeutically effective amount of a compound of the invention and a pharmaceutically acceptable carrier. This invention further provides a process for making a pharmaceutical composition comprising combining a therapeutically effective amount of a compound of the invention and a pharmaceutically acceptable carrier. This invention also provides a method of treating a subject suffering from depression and/or anxiety which comprises administering to the subject an amount of a compound of the invention effective to treat the subject's... | | Dibenzothiazepine derivatives and uses thereof - 424 | 20090318415 | 20091224 | | wherein Z is as described in the specification, pharmaceutically acceptable salts thereof, compositions comprising the same, and methods of treating bipolar disorder, an anxiety disorder, a mood disorder or schizophrenia or other psychotic disorder with said compounds.
... | | Substituted phenethylamines with serotoninergic and/or norepinephrinergic activity | 20090312435 | 20091217 | | Chemical syntheses and medical uses of novel inhibitors of the uptake of monoamine neurotransmitters and pharmaceutically acceptable salts and prodrugs thereof, for the treatment and/or management of psychotropic disorders, anxiety disorder, generalized anxiety disorder, depression, post-traumatic stress disorder, obsessive-compulsive disorder, panic disorder, hot flashes, senile dementia, migraine, hepatopulmonary syndrome, chronic pain, nociceptive pain, neuropathic pain, painful diabetic retinopathy, bipolar depression, obstructive sleep apnea, psychiatric disorders, premenstrual dysphoric disorder, social phobia, social anxiety disorder, urinary incontinence, anorexia, bulimia nervosa, obesity, ischemia, head injury, calcium overload in brain cells, drug dependence, and/or premature ejaculation are described.
... | | Cyclic hydroxylamine as psychoactive compounds | 20090312329 | 20091217 | | A compound of formula (I): in which X represents O or CH2; R3 and R4 each independently represent hydrogen or C1-6 alkyl; p represent 0 or 1; and R represents a five- or six-membered saturated or unsaturated ring selected from: formula (II), (III) and (IV); or R represents a five- or six-membered oxo-substituted unsaturated ring selected from: (V) and (VI); wherein R1 and R2 together represent an oxo group, or R1 and R2 each represent hydrogen, methoxy or ethoxy, or R1 and R2 together with the interjacent carbon atom represent a 1,3-dioxolane or 1,3-dioxane ring, attached via the 2 position and optionally bearing one or more methyl or ethyl groups; or a salt thereof, is suitable for the treatment of anxiety and depression.
... | | Pyrrolidine derivatives as nk2 receptor antagonists | 20090312327 | 20091217 | | wherein R1, R2, R3, Ar and n are as defined herein and pharmaceutically active salts, racemic mixtures, enantiomers, optical isomers or tautomeric forms thereof. The compounds can be used for the treatment of depression, anxiety or schizophrenia.
... | | Peptide having antianxiety activity and screening method therefor | 20090311185 | 20091217 | | The objects of the present invention are to provide a polypeptide having an antianxiety activity; a therapeutic agent containing the polypeptide; a method for treating anxiety using the polypeptide; a method of screening for a compound capable of activating or suppressing a receptor for the polypeptide and involved in the regulation of anxiety, a salt thereof, or a hydrate of them; and a kit for the screening. There is provided an antianxiety agent containing relaxin-3.
... | | 2-arylpyrazolo[l,5-alpha] pyrimidin-3-yl acetamide derivatives as ligands for translocator protein (18 kda) | 20090311176 | 20091217 | | The invention provides compounds of formula (I) radiolabelled with 18F, 123I, 76Br, 124I or 75Br and salts thereof, and a method of imaging translocator protein (18 kDa) (TSPO) in a subject comprising administering a compound of formula (I) radiolabelled with 18F, 123I, 76Br, 124I or 75Br or a pharmaceutically acceptable salt thereof. The invention further provides fluoro-substituted compounds of formula (II) and salts thereof, and a method of treating a neurodegenerative disorder, inflammation or anxiety in a subject comprising administering a compound of formula (II) or a pharmaceutically acceptable salt thereof.
... | | 2-amino-bicyclo (3.1.0) hexane-2,6-dicarboxylic ester derivative | 20090306408 | 20091210 | | [wherein R1 and R2 are identical or different, and each represents a hydrogen atom, a C1-10alkyl group or the like; X represents a hydrogen atom or a fluorine atom; Y represents —OCHR3R4 or the like (wherein R3 and R4 are identical or different, and each represents a hydrogen atom, a C1-10alkyl group or the like; and n represents integer 1 or 2)], a pharmaceutically acceptable salt thereof or a hydrate thereof.
... | | 3 or 4-substituted piperidine compounds | 20090306140 | 20091210 | | or any of their isomers, or pharmaceutically acceptable salts thereof. Also disclosed are pharmaceutical compositions containing the subject compounds. The subject compounds are useful for the treatment of diseases of the central nervous system, particularly depression, anxiety and pain disorder
... | | Aza-beta-carbolines and methods of using same | 20090306121 | 20091210 | | Further provided are pharmaceutical compositions comprising these compounds. The invention still further provides methods of treating alcoholism, methods of reducing alcohol intake, methods of treating anhedonia, and methods of treating anxiety using theses compounds or the compositions containing them.
... | | Pyrrolidine ether derivatives as nk3 receptor antagonists | 20090306043 | 20091210 | | wherein R1, R2, R3, R′, Ar, m, n, and o are as defined herein. The invention also relates to pharmaceutical compositions containing compounds of formula I and methods for the manufacture of such compounds and compositions. Compounds of the invention are high potential NK-3 receptor antagonists for the treatment of depression, pain, psychosis, Parkinson's disease, schizophrenia, anxiety and attention deficit hyperactivity disorder (ADHD).
... | | Phenyl piperazine compounds, pharmaceutical composition including the same and use thereof | 20090298831 | 20091203 | | The present invention relates to novel piperazine derivatives or pharmaceutically acceptable salts thereof, a process for preparing the same, and in particular, a high binding for Serotonin 1A(5-hydroxytryptamine; 5-HT1A) receptor, a pharmaceutical composition for treatment and/or prevention of depression and anxiety including an effective amount of the piperazine compound, and a method of treating depression, anxiety and other conditions related to 5-HT1A receptor in a mammal.
... | | Benzimidazolone derivatives | 20090298811 | 20091203 | | This invention relates to compounds and methods for the treatment of a condition mediated by CB1 receptor activity in a mammalian subject including a human, which comprises administering to a mammal in need of such treatment a therapeutically effective amount of the compound of formula (I) or pharmaceutically acceptable salts thereof, wherein: A, B, R1, R2 and R3 are each as described herein. These compounds are useful in the treatment of a condition mediated by CB2 receptor binding activity such as, but not limited to, inflammatory pain, nociceptive pain, neuropathic pain, fibromyalgia, chronic low back pain, visceral pain, acute cerebral ischemia, pain, chronic pain, acute pain, post herpetic neuralgia, neuropathies, neuralgia, diabetic neuropathy, HIV-related neuropathy, nerve injury, rheumatoid arthritic pain, osteoarthritic pain, back pain, cancer pain,... | | Medical system and method employing a drug delivery assembly | 20090292226 | 20091126 | | A medical system includes a muscular-tension-measuring device and a drug delivery assembly. The muscular-tension-measuring device is operatively connectable to a patient and includes a device output having a device output signal which varies with involuntary changes in muscular tension of the patient. The drug delivery assembly is operatively connectable to the patient for controllably delivering at least one drug to the patient. In one implementation, the device output signal varies with involuntary changes in muscular tension of the patient caused by pain and/or anxiety. In one employment, drug delivery is varied by a controller or a user based at least on variations in the device output signal. A method for conscious sedation of a patient includes measuring muscular tension of the patient and includes varying delivery... | | Aminopyrrolidine compound | 20090291940 | 20091126 | | Disclosed is an aminopyrrolidine compound represented by the formula [I] or a pharmaceutically acceptable salt thereof. The compound or the salt is useful as a prophylactic/therapeutic agent for mode disorder such as depression, anxiety disorder, anorexia, cachexia, pain and drug dependence, whose action relies on the MC4 receptor antagonistic effect.
... | | Therapeutic agent for psychoneurotic disease | 20090286862 | 20091119 | | (wherein the meanings of characters are defined in the description). This compound has an antagonistic potency against EP3 and exhibits efficacy through unusual action mechanism as a preventive and/or therapeutic agent for psychoneurotic disorder, psychosomatic disorder, anxiety disorder, depression and disorder caused by stress.
... | | 5,6,fused pyrrolidine compounds useful as tachykinin receptor antagonists | 20090286777 | 20091119 | | The present invention is directed to certain 5,6-fused pyrrolidine compounds which are useful as neurokinin-1 (NK-1) receptor antagonists, and inhibitors of tachykinin and in particular substance P. The invention is also concerned with pharmaceutical formulations comprising these compounds as active ingredients and the use of the compounds and their formulations in the treatment of certain disorders, including emesis, urinary incontinence, depression, and anxiety.
... | | Acyloxyalkyl carbamate prodrugs, methods of synthesis and use | 20090286759 | 20091119 | | Acyloxyalkyl carbamate prodrugs of 3-aminopropylphosphinic acid and analogs thereof, methods of making acyloxyalkyl carbamate prodrugs of 3-aminopropylphosphinic acid and analogs thereof, methods of using acyloxyalkyl carbamate prodrugs of 3-aminopropylphosphinic acid and analogs thereof, and pharmaceutical compositions comprising acyloxyalkyl carbamate prodrugs 3-aminopropylphosphinic acid and analogs thereof for treating diseases or disorders such as mild cognitive impairment, cognitive impairment associated with Alzheimer's disease Alzheimer's disease, depression, anxiety, and epilepsy are disclosed. Acyloxyalkyl carbamate prodrugs of 3-aminopropylphosphinic acid and analogs thereof, which are suitable for oral administration and sustained release oral dosage forms are also disclosed.
... | | Use of echinacea or preparations thereof in compositions for the treatment of anxiety | 20090285907 | 20091119 | | The present invention relates to the use of Echinacea or Echinacea preparations for the manufacture of pharmaceutical compositions which can be used to relieve natural occurrences of anxiety. The compositions can also be used to relieve the symptoms of various anxiety disorders including generalized anxiety, panic, acute traumatic stress disorder, post-traumatic stress disorder, phobias of various kinds including social phobia, compulsive disorders, and anxiety states related to withdrawal from drugs (e.g. alcohol, tobacco, and illicit drugs). The phrase “Echinacea” embraces Echinacea purpurea, Echinacea angustifolia, Echinacea pallida, or their combination. Echinacea preparations can be administered alone, but should preferably be used in combination with a vitamin mix (including but not limited to B1, B2, niacin, pantothenic acid, B6, biotin, folic acid B12, and/or C vitamin) and/or a... | | Apparatus for collecting the amniotic fluid from the uterus | 20090281456 | 20091112 | | An apparatus is provided for collecting amniotic fluid from the uterus. In order to collect the amniotic fluid from the uterus through the external orifice of the cervix of a pregnant woman, an amniotic fluid collecting unit is adapted to bring a mouth, which is foldably formed at the upper end of an amniotic fluid collecting bag, into close contact with an end of the external orifice of the cervix. Thereby, the apparatus not only significantly decreases the risk occurring when a needle is directly inserted into the uterus in order to carry out the amniocentesis (amniotic fluid testing), but also eliminates pain and anxiety caused by the direct insertion of the needle.
... | | Indolylalkyl derivatives of pyrimidinylpiperazine and metabolites thereof for treatment of anxiety, depression, and sexual dysfunction | 20090281114 | 20091112 | | The present invention relates to a method for alleviation, prevention, and treatment of anxiety, depression, and sexual dysfunction by administering certain indolylalkyl derivatives of pyrimidinylpiperazine or metabolites thereof. A preferred embodiment is of the following formula:
... | | Adatanserin and metabolites thereof for treatment of attention deficit disorder, anxiety, depression, sexual dysfunction, and other disorders | 20090281112 | 20091112 | | The present invention relates to a method for alleviation, prevention, and treatment of attention deficit disorder, anxiety, depression, sexual dysfunction, aggressive behavior, alcohol dependency, psychoses, and related conditions by administering adatanserin and/or metabolites of adatanserin. The present invention also relates to a method of weight loss by administering adatanserin and/or metabolites of adatanserin.
... | | Substituted pyrazinone derivatives for use as a medicine | 20090281099 | 20091112 | | a pharmaceutically acceptable acid or base addition salt thereof, a stereochemically isomeric form thereof, an N-oxide form thereof or a quaternary ammonium salt thereof, wherein the variables are defined in Claim 1, having selective α2C-adrenoceptor antagonist activity. It further relates to their preparation, compositions comprising them and their use as a medicine. The compounds according to the invention are usefull for the prevention and/or treatment of central nervous system disorders, mood disorders, anxiety disorders, stress-related disorders associated with depression and/or anxiety, cognitive disorders, personality disorders, schizoaffective disorders, Parkinson's disease, dementia of the Alzheimer's type, chronic pain conditions, neurodegenerative diseases, addiction disorders, mood disorders and sexual dysfunction.
... | | Apparatus for collecting the amniotic fluid from the uterus | 20090281456 | 20091112 | | An apparatus is provided for collecting amniotic fluid from the uterus. In order to collect the amniotic fluid from the uterus through the external orifice of the cervix of a pregnant woman, an amniotic fluid collecting unit is adapted to bring a mouth, which is foldably formed at the upper end of an amniotic fluid collecting bag, into close contact with an end of the external orifice of the cervix. Thereby, the apparatus not only significantly decreases the risk occurring when a needle is directly inserted into the uterus in order to carry out the amniocentesis (amniotic fluid testing), but also eliminates pain and anxiety caused by the direct insertion of the needle.
... | | Indolylalkyl derivatives of pyrimidinylpiperazine and metabolites thereof for treatment of anxiety, depression, and sexual dysfunction | 20090281114 | 20091112 | | The present invention relates to a method for alleviation, prevention, and treatment of anxiety, depression, and sexual dysfunction by administering certain indolylalkyl derivatives of pyrimidinylpiperazine or metabolites thereof. A preferred embodiment is of the following formula:
... | | Adatanserin and metabolites thereof for treatment of attention deficit disorder, anxiety, depression, sexual dysfunction, and other disorders | 20090281112 | 20091112 | | The present invention relates to a method for alleviation, prevention, and treatment of attention deficit disorder, anxiety, depression, sexual dysfunction, aggressive behavior, alcohol dependency, psychoses, and related conditions by administering adatanserin and/or metabolites of adatanserin. The present invention also relates to a method of weight loss by administering adatanserin and/or metabolites of adatanserin.
... | | Lightweight, hollow, reusable, food-dispensing treat toy and combination of food-dispensing treat toy with an enclosing container designed for intellectual stimulation, enrichment and amusement of animals, and reduction of boredom or separation anxiety th | 20080314331 | 20081225 | | This invention is directed toward a hollow food dispensing treat toy that can be filled and re-filled with animal food for unfrozen or frozen applications. The treat toy is designed to provide a mental and physical challenge to an animal desiring to lick out the contents of the container. The treat toys can be frozen in a conveniently-sized storage sleeve that fits in the shelf portion of an average freezer, and then removed at desired times. Whether unfrozen or frozen, the treat toys can be either given to the animal directly, or placed inside a larger hollow enclosing container with a hole such that the animal must align the holes in the containers to have easy access to the treat inside. Because of the design of... | | Method and compositions for treatment of add/adhd, depression, memory problems and other conditions | 20080317869 | 20081225 | | Disclosed herein are compositions and methods for treating a variety of mood and behavioral disorders, including attention deficit hyperactivity disorder (ADHD), anxiety, depression, memory loss, as well as other conditions. Also disclosed herein are methods for diagnosing certain conditions, such as ADHD, using these compositions.
... | | 1,3-dihydro-2h-indole-2-one compound and pyrrolidine-2-one compound fused with aromatic heterocycle | 20080318923 | 20081225 | | It is intended to provide a drug which is efficacious against pathological conditions relating to arginine-vasopressin V1b receptor. More particularly speaking, it is intended to provide a drug which has a therapeutic or preventive effect on depression, anxiety, Alzheimer's disease, Parkinson's disease, Huntington's chorea, eating disorders, hypertension, digestive diseases, drug addiction, epilepsy, brain infarction, brain ischemia, brain edema, head injury, inflammation, immune diseases, alopecia and so on. As the results of intensive studies, a novel 1,3-dihydro-2H-indol-2-one compound and a pyrrolidin-2-one compound fused with a heteroaromatic ring, which are highly selective antagonists of arginine-vasopressin V1b receptor, have high metabolic stabilities and show favorable brain penetration and high plasma concentrations, are found, thereby achieving the above objective.
... | | Compounds and uses thereof - 848 | 20080318943 | 20081225 | | and their pharmaceutically acceptable salts, tautomers or in vivo-hydrolysable precursors, compositions and methods of use thereof, wherein R1, R2, R3, R4, R5, and R6 are defined in the specification. These novel compounds provide a treatment or prophylaxis of anxiety disorders, schizophrenia, cognitive disorders, and/or mood disorders.
... | | Sulfonylpyrazole and sulfonylpyrazoline carboxamidine derivatives as 5-ht6 antagonists | 20080311179 | 20081218 | | and derivatives thereof, which are antagonists of 5-HT6 receptors, wherein the symbols have the meanings given in the description. The invention also concerns methods for the preparation of these compounds, to novel intermediates useful for their synthesis, and to uses of such compounds and compositions, particularly their use in administering them to patients to achieve a therapeutic effect in treating at least on disease or condition chosen from Parkinson's disease, Huntington's chorea, schizophrenia, anxiety, depression, manic depression, psychoses, epilepsy, obsessive compulsive disorders, mood disorders, migraine, Alzheimer's disease, age related cognitive decline, mild cognitive impairment, sleep disorders, eating disorders, anorexia, bulimia, binge eating disorders, panic attacks, akathisia, attention deficit hyperactivity disorder, attention deficit disorder, withdrawal from abuse of cocaine, ethanol, nicotine or benzodiazepines, pain, disorders associated with... | | Game server, game machine, game control server, and game control method | 20080311982 | 20081218 | | The cumulative credit consumptions of game machines are controlled per player. When the cumulative credit consumption of a player reaches an upper limit, a return is executed to the player based on a predetermined return rate. In addition, the return rate can be changed to produce high game characteristics. Therefore, the player can perform a game without anxiety, while enjoying amusement of the game. At the result, the problem of missing customers can be eliminated.
... | | Inhibitors of the 11-beta-hydroxysteroid dehydrogenase type 1 enzyme | 20080312214 | 20081218 | | or a pharmaceutically acceptable salt, prodrug, salt of a prodrug, or a combination thereof. Methods of inhibiting 11-beta-hydroxysteroid dehydrogenase Type 1 enzyme. Methods of treating neuronal degeneration, dysfunction, acute psychosis, anxiety, dementia, depression, non-insulin dependent type 2 diabetes, insulin resistance, obesity, lipid disorders, metabolic syndrome and other diseases and conditions that are mediated by excessive glucocorticoid action.
... | | Piperazine and [1,4]diazepan derivatives as nk antagonists | 20080312216 | 20081218 | | R9, R10, m and n are as defined herein, or to a pharmaceutically acceptable acid addition salt thereof. The present compounds are high potential NK-3 receptor antagonists for the treatment of depression, bipolar disorders, pain, psychosis, Parkinson's disease, schizophrenia, anxiety and attention deficit hyperactivity disorder (ADHD).
... | | Fused tetracyclic mglur1 antagonists as therapeutic agents | 20080312218 | 20081218 | | In its many embodiments, the present invention provides tetracyclic compounds of formula I or formula II (wherein the various moieties are as defined herein) useful as metabotropic glutamate receptor (mGluR) antagonists, particularly as selective metabotropic glutamate receptor 1 antagonists, pharmaceutical compositions containing the compounds, and methods of treatment using the compounds and compositions to treat diseases associated with metabotropic glutamate receptor (e.g., mGluR1) such as, for example, pain, migraine, anxiety, urinary incontinence and neurodegenerative diseases such Alzheimers disease.
... | | Pharmaceutical compositions containing pyrazole derivatives for treating as serotonin antagonist | 20080312253 | 20081218 | | The present invention relates to a pharmaceutical composition containing a pyrazole derivative as an active ingredient, which has antagonistic activity against serotonin 5-HT3A and is effective for the prevention and treatment of central nervous system (CNS) diseases, including emesis, nausea, alcoholism, drug abuse, depression, compulsive neurosis, anxiety, seizure, Alzheimer's disease, Parkinson's disease, Huntington's chorea, psychosis, schizophrenia, suicidal tendency, sleep disorder, appetite disorder and migraine.
... | | Substituted tricyclic piperidone compounds | 20080312268 | 20081218 | | a method for producing such compounds; pharmaceutical compositions containing such compounds, and the use of such compounds to treat pain, depression, urinary incontinence, diarrhea, pruritus, alcohol and drug abuse, drug dependency, lethargy and/or anxiety.
... | | Imidazole derivatives and their use for modulating the gabaa receptor complex | 20080312303 | 20081218 | | The compounds of the invention are useful in the treatment of central nervous system diseases and disorders, which are responsive to modulation of the GABAA receptor complex, and in particular for combating anxiety and related diseases.
... | | Neurosurgical candidate selection tool | 20080312513 | 20081218 | | A system and method for neurosurgery candidacy assessment includes multiple data sources, wherein results of tests from at least some of the multiple data sources are integrated. A neurosurgery candidacy assessment report including a recommendation regarding candidacy for neurosurgery is provided based on the integrated results. The multiple data sources may include cognitive tests, a background data source, a medical data source, an anxiety/depression data source, and a motor skills data source. The medical data source may include a FLASQ-PD questionnaire.
... | | Prolinamide derivatives as nk3 antagonists | 20080306086 | 20081211 | | X, n, and o are as defined herein and to a pharmaceutically acceptable acid addition salt thereof which are high potential NK-3 receptor antagonists for the treatment of depression, pain, psychosis, Parkinson's disease, schizophrenia, anxiety and attention deficit hyperactivity disorder (ADHD).
... | | Prolinamide-tetrazole derivatives as nk3 receptor antagonists | 20080306089 | 20081211 | | R1, R2, R3, and n are as defined herein or to a pharmaceutically acceptable acid addition salt thereof. These compounds are NK3 receptor antagonists, useful for the treatment of such disorders as depression, pain, bipolar disorders, psychosis, Parkinson's disease, schizophrenia, anxiety, and attention deficit hyperactivity disorder (ADHD).
... | | Pde10 inhibitors and related compositions and methods | 20080300240 | 20081204 | | wherein m, n, p, x, R, R1, R2, R3, R4, R5, A and B, are defined herein, including pharmaceutically acceptable salts, stereoisomers, solvates or prodrugs thereof. Also disclosed are compositions containing a compound of this invention in combination with a pharmaceutically acceptable carrier, as well as methods relating to the use thereof for inhibiting PDE 10 in a warm-blooded animal in need of the same.
... | | Multimediator 5-ht6 receptor antagonists, and uses related thereto | 20080300259 | 20081204 | | The invention provides a class of 5HT6—D3/DAT compounds, packaged pharmaceuticals comprising such compounds, and their uses in treating, or manufacturing medicaments for treating disease conditions, including a movement disorder, anxiety, depression or psychotic disorder (e.g. Bipolar Disorder, Bipolar Depression or Unipolar Depression, etc.). Related business methods such as marketing the compounds to healthcare providers are also provided.
... | | Compositions and methods for treating mood and anxiety disorders | 20080292627 | 20081127 | | The invention relates method of disrupting the interface between Gsα and tubulin. The disruption of this interaction is a mechanism for treatment of mood and anxiety disorders and this interaction may be used to screen for and design therapeutics for mood and anxiety disorders.
... | | Game server, game machine, and game control method | 20080293496 | 20081127 | | In a collective control of plural game machines placed in the same parlor, it is detected whether there is a player change with each game machine and, based on the detection result, the cumulative credit consumption with each game machine is controlled per player. When the cumulative credit consumption of a certain player reaches a predetermined upper limit, return is executed to this player. The upper limit value is changed properly. Therefore, the player can perform a game without anxiety while enjoying amusement of the game. As the result, it may be avoided losing customers.
... | | Game server, game machine under control of the server, and game control method | 20080293497 | 20081127 | | In a game center installing a plurality of game machine groups (G01, G02, . . . and G10) as a collection of game machines (2), a game server (1) collectively controls the cumulative credit consumption of the individual game machine groups (G01, G02, . . . and G10). With the configuration, when the cumulative credit consumption of a certain game machine group reaches a predetermined upper limit, a return is executed to a certain game machine (2) of this game machine group. Therefore, it is possible to provide such circumstances that the player can perform a game without anxiety, while enjoying amusement of the game. At the result, the problem of missing customers is solvable.
... | | Therapeutic pyrazolo[3,4-b]pyridines and indazoles | 20080293715 | 20081127 | | wherein R2, R3, R4, R5, R6, R7, X, and L have any of the values defined in the specification, and pharmaceutically acceptable salts thereof, that are useful as agents in the treatment of central nervous disorders and conditions including attention deficit hyperactivity disorder, neuropathic pain, urinary incontinence, anxiety, depression, and schizophrenia and fibromyalgia. Also provided are pharmaceutical compositions comprising one or more compounds of Formula I.
... | | Combinations of eszopiclone and trans 4-(3,4-dichlorophenyl)-1,2,3,4-tetrahydro-n-methyl-1-napthalenamine or trans 4-(3,4-dichlorophenyl)-1,2,3,4-tetrahydro-1-napthalenamine, and methods of treatment of menopause and mood, anxiety, and cognitive disorders | 20080293726 | 20081127 | | One aspect of the present invention relates to pharmaceutical compositions containing two or more active agents that when taken together can be used to treat, e.g., menopause, mood disorders, anxiety disorders, or cognitive disorders. The first component of the pharmaceutical composition is a sedative eszopiclone. The second component of the pharmaceutical composition is trans 4-(3,4-dichlorophenyl)-1,2,3,4-tetrahydro-N-methyl-1-napthalenamine or trans 4-(3,4-dichlorophenyl)-1,2,3,4-tetrahydro-1-napthalenamine. The present invention also relates to a method of treating menopause, perimenopause, mood disorders, anxiety disorders, and cognitive disorders.
... | | Novel arylbicyclo[3.1.0]hexylamines and methods and compositions for their preparation and use | 20080293822 | 20081127 | | The invention provides novel arylbicyclo[3.1.0]hexylamines, and related processes and intermediates for preparing these compounds, as well as compositions and methods employing these compounds for the treatment and/or prevention of central nervous system (CNS) disorders, including but not limited to depression and anxiety.
... | | Compositions and methods for treatment of neurological symptoms associated with alcohol-withdrawal and for consulsive seizure | 20080286209 | 20081120 | | Particular aspects of the present invention provide pharmaceutical compositions comprising isoprenoid-based compounds (e.g., farnesol and/or farnesol analogues or derivatives) or dehydroisoprenoid-based compounds, and novel methods for using same in treating (e.g., suppressing): alcohol withdrawal syndrome and associated neurological symptoms (e.g., depression, tremor, anxiety, autonomic hyperactivity (e.g., sweating, increased blood pressure, tachycardia), hallucinations, alcohol withdrawal seizures, delirium tremens (DT), and memory loss); or for treating in treating convulsive seizure (e.g., epileptic seizure, etc.). Particular pharmaceutical compositions and methods comprise the use of at least one compound selected from the group consisting of: (2E,6E)-3,7,11-trimethyldodeca-2,6,10-trien-1-ol (all-trans farnesol); (2Z,6E)-3,7,11-trimethyldodeca-2,6,10-trien-1-ol (cis-farnesol); (E)-3,7,11-trimethyldodeca-1,6,10-trien-3-ol nerolidol); (2E,6E)-3,7,11-trimethyldodeca-2,6,10-trien-1-amine (farnesylamine); (E)-3-(3,7-dimethylocta-2,6-dienyloxy)phenol (geranylresorcinol); (2E,6E)-,7,11-dimethyl-3-(trifluoromethyl)dodeca-2,6,10-trien-1-ol (trifluorofarnesol); and (2E,4E,6E,8E)-3,7-dimethyl-9-(2,6,6-trimethylcyclohex-1-enyl)nona-2,4,6,8-tetraen-1-ol (all-trans retinol). According to additional aspects, compounds that target and inhibit enzymes that degrade/metabolize/inactivate the disclosed compounds have utility to... | | Pyrrolopyrimidine derivatives substituted with cyclic amino group | 20080287397 | 20081120 | | An object of the present invention is to provide an antagonist against CRF receptors which is effective as a therapeutic or prophylactic agent for diseases in which CRF is considered to be involved, such as depression, anxiety, Alzheimer's disease, Parkinson's disease, Huntington's chorea, eating disorder, hypertension, gastric diseases, drug dependence, epilepsy, cerebral infarction, cerebral ischemia, cerebral edema, cephalic external wound, inflammation, immunity-related diseases, alopecia, irritable bowel syndrome, sleep disorders, epilepsy, dermatitides, schizophrenia, etc. This problem can be solved with a pyrrolopyrimidine or pyrrolopyridine derivative substituted with a cyclic amino group represented by formula [I] below which has a high affinity for CRF receptors and is effective against diseases in which CRF is considered to be involved.
... | | Cb1 modulator compounds | 20080287504 | 20081120 | | Novel compounds of structural formula (I) are disclosed. As modulators of the Cannabinoid-1 (CB1) receptor, these compounds are useful in the treatment, prevention and suppression of diseases mediated by the CB1 receptor. As such, compounds of the present invention are useful as in the treatment, prevention and suppression of psychosis, memory deficits, cognitive disorders, migraine, neuropathy, neuro-inflammatory disorders (e.g., multiple sclerosis, Guillain-Barre syndrome and the inflammatory sequelae of viral encephalitis), cerebral vascular accidents, head trauma, anxiety disorders, stress, epilepsy, Parkinson's disease, and schizophrenia. The compounds are also useful for the treatment of substance abuse disorders, particularly to opiates, alcohol, and nicotine. The compounds are also useful for the treatment of obesity or eating disorders associated with excessive food intake and complications associated therewith.
... | | Novel isovaleramide forms, compositions thereof, and related methods of use | 20080287542 | 20081120 | | The invention provides novel isovaleramide forms. These forms include isovaleramide co-crystals, and solvates, hydrates, co-crystals, and polymorphs thereof. The invention also provides novel compositions comprising these novel forms and one or more suitable carriers. The invention also provides related methods of treatment or prevention. Compositions and methods of the invention have a number of uses, including the treatment or prevention of epilepsy and anxiety.
... | | On-vehicle navigation system | 20080288163 | 20081120 | | The present invention provides an on-vehicle navigation system in which a user can perform predetermined driving using a special lane such as a carpool lane appropriately and without anxiety where advancing from a normal lane in a predetermined advancing authorized section and exiting to the normal lane in a predetermined exiting authorized section are authorized. The system includes a remaining number notifying section for notifying the user of the remaining number of at least one of an exiting authorized section for exiting from a special lane to the normal lane and an advancing authorized section for advancing to the special lane from a normal lane, between a vehicle position detected by a vehicle position calculation section and an interchange point or an exit of a plural-lane... | | Biaryl substituted pyrazinones as sodium channel blockers | 20080280873 | 20081113 | | Biaryl substituted pyrazinone compounds represented by Formula I, or pharmaceutically acceptable salts thereof. Pharmaceutical compositions comprise an effective amount of the instant compounds, either alone, or in combination with one or more other therapeutically active compounds, and a pharmaceutically acceptable carrier. Methods of treating conditions associated with, or caused by, sodium channel activity, including, for example, acute pain, chronic pain, visceral pain, inflammatory pain, neuropathic pain, urinary incontinence, itchiness, allergic dermatitis, epilepsy, irritable bowel syndrome, depression, anxiety, multiple sclerosis, and bipolar disorder, comprise administering an effective amount of the present compounds, either alone, or in combination with one or more other therapeutically active compounds. A method of administering local anesthesia comprises administering an effective amount of a compound of the instant invention, either alone, or in... | | Methods for treating anxiety related disorders | 20080280885 | 20081113 | | The present invention relates to methods of and compositions for treating and relieving symptoms and disease associated with indications caused by a physiological drive to alleviate a sensation of anxiety. In one treatment method, methods of, and compositions for, modulating the expression of certain GABAA receptor subunits are used to treat anxiety-related disorders and depressive disorders associated with physiological tolerance to endogenous neurosteroids.
... | | Quinoline tachykinin receptor antagonists | 20070293492 | 20071220 | | The present invention is directed to certain quinoline compounds which are useful as neurokinin-1 (NK-1) receptor antagonists, and inhibitors of tachykinin and in particular substance P. The invention is also concerned with pharmaceutical formulations comprising these compounds as active ingredients and the use of the compounds and their formulations in the treatment of certain disorders, including emesis, urinary incontinence, depression, and anxiety.
... | | 1,3-disubstituted heteroaryl nmda/nr2b antagonists | 20070293515 | 20071220 | | (wherein A, B, D, P, Q, R1, R2, R3, W and Y are described herein) or pharmaceutically acceptable salts thereof, are effective as NMDA/NR2B antagonists useful for treating neurological conditions such as, for example, pain, Parkinson's disease, Alzheimer's disease, epilepsy, depression, anxiety, ischemic brain injury including stroke, and other conditions.
... | | Pyrrolopyrimidine and pyrrolopyridine derivatives substituted with tetrahydropyridine as crf antagonists | 20070293670 | 20071220 | | has a high affinity for CRF receptors and is effective against diseases in which CRF is considered to be involved.
... | | Amino acid compositions | 20070286909 | 20071213 | | Compositions are described herein that are nutritional supplements that contain free amino acids. These supplements contain a homogenous mixture of free amino acids, wherein the free-form amino acids comprise L-Lysine, L-Valine, L-Tryptophan, L-Phenylalanine, L-methionine, L-Leucine, L-Threonine, L-Isoleucine, L-Arginine, L-Histidine, L-Tyrosine, L-Carnitine, L-Serine, L-Glutamine, Aspartic Acid, L-Proline, L-Glycine, Taurine, L-Cysteine, Gamma-aminobutyric acid (GABA), L-Alanine, L-Glutamic acid, and wherein the composition comprises at least one B vitamin. These compositions are of use to treat disorders associated with a deficiency at least one amino acid, such as soft tissue injury, insomnia, panic attacks, anxiety disorders, eating disorders, anorexia, depression, chronic pain, emotional distress, chemical dependence, alcoholism, and hypoglycemia.
... | | Preparation and utility of substituted pyrazole compounds with cannabinoid receptor activity | 20070287734 | 20071213 | | The present disclosure is directed to modulators of CB-1 type receptors and pharmaceutically acceptable salts and prodrugs thereof, the chemical synthesis thereof, and the medical use of such compounds for the treatment and/or management of the severity and duration of obesity, metabolic syndrome, dyslipidemia, glucose imbalance, the inability to maintain weight loss, insulin resistance, a cardiovascular disorder, memory loss, drug dependence, a depressive disorder, a panic disorder, an obsessive-compulsive disorder, anxiety, post-traumatic stress syndrome, and any other condition in which it is beneficial to inhibit, inversely agonize or modulate a cannabinoid receptor are described.
... | | Argon-based inhalable gaseous medicinal product for the treatment of neurointoxications | 20070275089 | 20071129 | | The invention relates to the use of argon gas for producing all or part of an inhalable medicinal product intended to prevent or treat a neurointoxication in humans. The medicinal product contains argon in an effective proportion and acts on at least one brain receptor in order to regulate the functioning of dopamine-, glutamate-, serotonin-, acetylcholine-, taurine-, GABA- and/or noradrenalin-mediated neurotransmission systems. Preferably, the proportion by volume of argon in the gaseous medicinal product is between 15 and 80%. The neurointoxication is chosen from excitotoxicities engendering a state of addiction, acute cerebral accidents, neurodegenerative diseases, and psychiatric or neurological pathologies, in particular anxiety conditions, psychotic conditions, in particular schizophrenia, and epilepsy in its various forms.
... | | Novel thieno-pyridine and thieno-pyrimidine derivatives and their use as positive allosteric modulators of mglur2-receptors | 20070275984 | 20071129 | | The present invention relates to novel compounds, in particular novel thieno-pyridine and thieno-pyrimidine derivatives according to Formula (I), wherein all radicals are defined in the application. The compounds according to the invention are positive allosteric modulators of metabotropic receptors—subtype 2 (“mGluR2”) which are useful for the treatment or prevention of neurological and psychiatric disorders associated with glutamate dysfunction and diseases in which the mGluR2 subtype of metabotropic receptors is involved. In particular, such diseases are central nervous system disorders selected from the group of anxiety, schizophrenia, migraine, depression, and epilepsy. The invention is also directed to pharmaceutical compositions and processes to prepare such compounds and compositions, as well as to the use of such compounds for the prevention and treatment of such diseases in which mGluR2... | | Treatment of neurotic disorders | 20070276035 | 20071129 | | Use of escitalopram (the S-(+)-enantiomer of citalopram) or a pharmaceutically acceptable salt thereof for the preparation of a medicament useful in the treatment of neurotic disorders is provided, including anxiety states, in particular generalized anxiety disorder and social anxiety disorder, post traumatic stress disorder, obsessive compulsive disorder and panic attacks.
... | | Spirocyclic heterocyclic derivatives and methods of their use | 20070269374 | 20071122 | | Spirocyclic heterocyclic derivatives, pharmaceutical compositions containing these compounds, and methods for their pharmaceutical use are disclosed. In certain embodiments, the spirocyclic heterocyclic derivatives are ligands of the δ-opioid receptor and may be useful, inter alia, for treating and/or preventing pain, anxiety, gastrointestinal disorders, and other δ-opioid receptor-mediated diseases, disorders, and/or conditions.
... | | Methods of treating constipation by administration of nerve growth factor | 20070270347 | 20071122 | | Method for administering nerve growth factor to treat various psychological conditions such as of depression, bi-polar disorders, anxiety disorders, panic attacks, agoraphobia, and attention deficit syndrome, and alleviate symptoms associated with premenstrual syndrome (PMS), premenstrual dysphoric disorder (PMDD), sleep disorders, tension headaches, and constipation that arise as complications from a psychological condition. Also provided are methods of treating constipation comprising administering nerve growth factor in amount effective to treat constipation. Pharmaceutical compositions for the treatment of constipation comprising nerve growth factor are also provided.
... | | Substituted propane phosphinic acid esters | 20070270385 | 20071122 | | wherein R, R1 and R2 are as defined herein. The compounds of this invention are useful in treating a variety of diseases including but not limited to depression, anxiety, certain psychiatric symptoms, cognitive impairment and schizophrenia.
... | | Pyrrolopyrimidine derivatives | 20070270588 | 20071122 | | has a high affinity for CRF receptors and is effective against diseases in which CRF is considered to be involved.
... | | Bulb syringe nasal protection device | 20070270736 | 20071122 | | An improvement in bulb syringes which essentially prevents the bulb syringe from entering too far into the nasal cavity of a baby or infant when removing mucus from the child's nose, thereby allowing easier breathing for the child. The device is a guard member and is screwed onto the bulb syringe and is made of a soft plastic material. When the bulb syringe is used to suction, the guard member impedes the stem of the bulb syringe from going too far into the nasal passages of a baby, which reduces discomfort, anxiety and pain in the child. Generally the invention is applicable to any previously patented bulb syringe, no matter the shape or size of the syringe, and is a unique improvement on existing bulb syringes.
... | | Composition containing an extract of rubi fructus for preventing and treaing anxiety, depression and dementia and improving memory | 20070259062 | 20071108 | | Disclosed is a composition containing an extract of Rubi Fructus for preventing and treating anxiety, depression and dementia and improving memory. The composition can be used as drugs and dietary supplements which induce prophylactic and therapeutic effects on anxiety, depression and dementia as well as memory-improving effect in the modems afflicted with the modification of neurotransmitter releases and brain damage caused by external environmental factors including various kinds of stresses, menopause, drinking alcohols, smoking cigarettes and others.
... | | Amorphous form of olanzapine | 20070259857 | 20071108 | | The present invention relates to an amorphous form of olanzapine Formula (I): and a process for its preparation. The present invention further relates to a pharmaceutical composition comprising an amorphous form of olanzapine (I). The pharmaceutical composition may be used, in particular, for the treatment of psychiatric, psychological or psychotic disorders, anxiety disorders, or gastrointestinal or functional bowel disorders. The present invention also relates to a method of treating said disorders.
... | | Use of gal3 antagonist for treatment of depression and/or anxiety and compounds useful in such methods | 20070259942 | 20071108 | | This invention is directed to pyrimidine and indolone derivatives which are selective antagonists for the GAL3 receptor. The invention provides a pharmaceutical composition comprising a therapeutically effective amount of a compound of the invention and a pharmaceutically acceptable carrier. This invention also provides a pharmaceutical composition made by combining a therapeutically effective amount of a compound of the invention and a pharmaceutically acceptable carrier. This invention further provides a process for making a pharmaceutical composition comprising combining a therapeutically effective amount of a compound of the invention and a pharmaceutically acceptable carrier. This invention also provides a method of treating a subject suffering from depression and/or anxiety which comprises administering to the subject an amount of a compound of the invention effective to treat the subject's... | | Thienopyrimidine and thienopyridine derivatives substituted with cyclic amino group | 20070254898 | 20071101 | | has a high affinity for CRF receptors and is effective against diseases in which CRF is considered to be involved.
... | | Substituted diaza-spiro-[4.5]-decane derivatives and their use as neurokinin antagonists | 20070254904 | 20071101 | | and comprises also the pharmaceutically acceptable acid or base addition salts thereof, the stereochemically isomeric forms thereof, the N-oxide form thereof and prodrugs thereof, wherein all substituents are defined as in Claim 1.
... | | Molecules | 20070248995 | 20071025 | | This invention relates to the gene encoding gerbil neurokinin 1 receptor (gNK1r) and to proteins encoded by the gene, as well as to means of regulating their biological activity. In addition the invention relates to the use of the gene and protein to identify therapeutic agents for controlling asthma, pain, depression, anxiety, emesis, inflammatory bowel disease (IBD), irritable bowel syndrome (IBS), functional dyspepsia, migraine, urinary incontinence and schizophrenia.
... | | Triazolobenzodiazepines and their use as vasopressin antagonists | 20070249585 | 20071025 | | R1 and R2 independently represent C1-6 alkyl; and Ring A represents a phenyl ring or a pyridinyl ring; may be useful in the treatment of anxiety, cardiovascular disease (including angina, atherosclerosis, hypertension, heart failure, edema, hypernatremia), dysmenorrhoea (primary and secondary), endometriosis, emesis (including motion sickness), intrauterine growth retardation, inflammation (including rheumatoid arthritis), mittlesmerchz, preclampsia, premature ejaculation, premature (preterm) labor and Raynaud's disease.
... | | 3-monosubstituted tropane derivatives as nociceptin receptor ligands | 20070249604 | 20071025 | | R7 is H or alkyl; and m and n are each 0-6, provided that the sum of m and n is 0-6; or a pharmaceutically acceptable salt or solvate thereof, pharmaceutical compositions thereof, and the use of said compounds in the treatment of cough, pain, anxiety, asthma, depression, alcohol abuse, urinary incontinence and overactive bladder are disclosed.
... | | Diarylmethyl piperazine derivatives, preparations thereof and uses thereof | 20070249619 | 20071025 | | Compounds of general formula: as well as salts, enantiomers thereof and pharmaceutical compositions including the compounds are prepared. They are useful in therapy, in particular in the management of pain, depression and anxiety.
... | | P2x7 antagonists to treat affective disorders | 20070249666 | 20071025 | | The present invention provides methods to treat mood disorders and anxiety disorders using antagonists of the P2X7 receptor and pharmaceutical compositions thereof, or combinations.
... | | Genetic variants of human inositol polyphosphate-4-phosphatase, type i (inpp4a) useful for prediction and therapy of immunological disorder | 20070243539 | 20071018 | | Atopic asthma is a chronic, inflammatory lung disease characterized by recurrent breathing problems in response to an allergen. Platelets play an important role in this allergic inflammatory process, by releasing preformed mediators like platelet factor 4 (PF4) and regulated upon activation in normal T cells expressed and secreted (RANTES) upon activation causing eosinophil chemotaxis. The present invention relates to allelic variants of the human Inositol polyphosphate 4-phosphatase (INPP4A) gene and splice variants of the coding sequence, which encodes INPP4A enzyme known to be an important regulator of platelet activation; and provides primers and methods suitable for the detection of these allelic variants for applications such as molecular diagnosis, prediction and prevention of an individual's disease susceptibility, and/or the genetic analysis of the INPP4A gene in a... | | Enzyme inhibitors | 20070244177 | 20071018 | | R1, R2, R3, R4 and R5 are defined throughout the description and the claims. The compounds of formula (I) are useful for the treatment of neurological diseases and neurodegenerative diseases, e.g. anxiety, depression, Alzheimer's disease etc.
... | | Use of antagonists of hepatic sympathetic nerve activity | 20070238762 | 20071011 | | The present invention provides pharmaceutical compositions comprising antagonists of hepatic sympathetic activity and methods for using said pharmaceutical compositions for treatment of hyperglycemia, hyperinsulinaemia, hyperlipidaemia, hypertriglyceridaemia, diabetes, insulin resistance, impaired glucose metabolism, conditions of impaired glucose tolerance, conditions of impaired fasting plasma glucose, obesity, diabetic retinopathy, diabetic nephropathy, glomerulosclerosis, diabetic neuropathy, syndrome X, renal failure, sexual dysfunction, chronic stress, and anxiety.
... | | Methods and pharmaceutical compositions for treatment of anti-estrogen resistant breast cancer using rxr modulators | 20070238792 | 20071011 | | The present invention relates to the use of agomelatine, or N-[2-(7-methoxy-1-naphthyl)ethyl]acetamide, in obtaining medicaments intended for the treatment of Generalized Anxiety Disorder.
... | | Uses of polypeptides | 20070232538 | 20071004 | | The present invention provides uses of a polypeptide having a ligand activity to a sensory epithelium neuropeptide-like receptor (SENR) which is a G protein-coupled receptor protein, and a DNA encoding the same. More specifically, the present invention provides an anti-attention-deficit-disorder or anti-narcolepsy agent, which comprises a polypeptide having a ligand activity for SENR or a salt thereof, as well as a method for screening compounds having an anti-attention-deficit-disorder or anti-narcolepsy activity or compounds having an anti-anxiety, anti-depression, anti-insomnia, anti-schizophrenia or anti-fear activity or salts thereof, which comprises using the above polypeptide or a precursor protein of the polypeptide or a salt thereof.
... | | Substituted diaza-spiro-[5.5]-undecane derivaties and their use as neurokinin antagonists | 20070232636 | 20071004 | | and comprises also the pharmaceutically acceptable acid or base addition salts thereof, the stereochemically isomeric forms thereof, the N-oxide form thereof and prodrugs thereof, wherein all substituents are defined as in Claim 1.
... | | Serotonin transporter (sert) inhibitors for the treatment of depression and anxiety | 20070232652 | 20071004 | | The compounds of formula I are good inhibitors of the serotonin transporter (SERT inhibitors) and simultaneously, they have good activity on the NK-1 receptor (dual effect). By virtue of their efficacy as SERT inhibitors, the compounds in the present invention are particularly useful for the treatment of CNS disorders and psychotic disorders, in particular in the treatment or prevention of depressive states and/or in the treatment of anxiety.
... | | Substituted 3-alkyl and 3-alkenyl azetidine derivatives | 20060293299 | 20061228 | | Novel compounds of the structural formula (I) are antagonists and/or inverse agonists of the Cannabinoid-1 (CB1) receptor and are useful in the treatment, prevention and suppression of diseases mediated by the CB1 receptor. The compounds of the present invention are useful as centrally acting drugs in the treatment of psychosis, memory deficits, cognitive disorders, migraine, neuropathy, neuro-inflammatory disorders including multiple sclerosis and Guillain-Barre syndrome and the inflammatory sequelae of viral encephalitis, cerebral vascular accidents, and head trauma, anxiety disorders, stress, epilepsy, Parkinson's disease, movement disorders, and schizophrenia. The compounds are also useful for the treatment of substance abuse disorders, the treatment of obesity or eating disorders, as well as the treatment of asthma, constipation, chronic intestinal pseudo-obstruction, and cirrhosis of the liver.
... | | Antidepressant azaheterocyclylmethyl derivatives of heterocycle-fused benzodioxans | 20060293301 | 20061228 | | are useful for the treatment of depression (including but not limited to major depressive disorder, childhood depression and dysthymia), anxiety panic disorder, post-traumatic stress disorder, premenstrual dysphoric disorder (also known as premenstrual syndrome), attention deficit disorder (with and without hyperactivity), obsessive compulsive disorder, social anxiety disorder, generalized anxiety disorder, obesity, eating disorders such as anorexia nervosa and bulimia nervosa, vasomotor flushing, cocaine and alcohol addiction, sexual dysfunction and related illnesses.
... | | New phenylpiperazines | 20060293313 | 20061228 | | R7 is alkyl (1-3C), alkoxy (1-3C), halogen or cyano; or R6+R7 (R7 at position 7 of the indole group) represent a group —(CH2)q wherein q has the value 2-4, and salts thereof.
... | | Biaryl substituted 6-membered heterocycles as sodium channel blockers | 20060293339 | 20061228 | | Biaryl substituted pyridine, pyrimidine and pyrazine compounds are sodium channel blockers useful for the treatment of pain. Pharmaceutical compositions comprise an effective amount of the instant compounds, either alone, or in combination with one or more therapeutically active compounds, and a pharmaceutically acceptable carrier. Methods of treating conditions associated with, or caused by, sodium channel activity, including, for example, acute pain, chronic pain, visceral pain, inflammatory pain, neuropathic pain, epilepsy, irritable bowel syndrome, depression, anxiety, multiple sclerosis, and bipolar disorder, comprise administering an effective amount of the present compounds, either alone, or in combination with one or more other therapeutically active compounds.
... | | Alkyl sulfonamide derivatives | 20060293341 | 20061228 | | This invention is directed to alkyl sulfonamide derivatives which are ligands at the NPY Y5 receptor. The invention provides a pharmaceutical composition comprising a therapeutically effective amount of a compound of the invention and a pharmaceutically acceptable carrier. This invention also provides a pharmaceutical composition made by admixing a therapeutically effective amount of a compound of the invention and a pharmaceutically acceptable carrier. This invention further provides a process for making a pharmaceutical composition comprising combining a therapeutically effective amount of a compound of the invention and a pharmaceutically acceptable carrier. This invention also provides a method of treating a subject suffering from depression which comprises administering to the subject an amount of a compound of the subject invention. This invention also provides a method of... | | 5-chloro-4-alkyl-3,4-dihydro-quinazolin-2-ylamine derivatives | 20060293349 | 20061228 | | Compounds of formula I have good activity on the 5-HT5A receptor. Therefore, the invention provides a method for treating diseases related to this receptor, for example, anxiety, depression, sleep disorders and schizophrenia.
... | | 8-alkoxy or cycloalkoxy-4-methyl-3,4-dihydro-quinazolin-2-ylamines | 20060293350 | 20061228 | | n are as described in the specification and pharmaceutically acceptable acid addition salts thereof. The compounds of formula I can be used for the treatment of 5-HT5A receptor antagonists related diseases, which include depression, anxiety disorders, schizophrenia, panic disorders, agoraphobia, social phobia, obsessive compulsive disorders, post-traumatic stress disorders, pain, memory disorders, disorders of eating behaviors, sexual dysfunction, sleep disorders, withdrawal from abuse of drugs, motor disorders such as Parkinson's disease, dementia in Parkinson's disease, neuroleptic-induced Parkinsonism and tardive dyskinesias, as well as other psychiatric disorders and gastrointestinal disorders such as irritable bowel syndrome.
... | | 4-(2-phenyloxyphenyl)-piperidine or-1,2,3,6-tetrahydropyridine derivatives as serotonin reuptake inhibitors | 20060293360 | 20061228 | | The invention provides compounds represented by the general formula (I) wherein the substituents are defined in the application. The compounds are useful in the treatment of an affective disorder, including depression, anxiety disorders including general anxiety disorder and panic disorder and obsessive compulsive disorder.
... | | Combinations of paroxetine and 2-(r)-(4-fluoro-2-methyl-phenyl)-4-(s)-((8as)-6-oxo-hexahydro-pyrrolo'1,2-a!-pyrazin-2-yl)-piperidine-1-carboxylicacid'1-(r)-(3,5-bis-trifluoromethyl-phenyl)- | 20060287325 | 20061221 | | The present invention relates to therapeutic combinations comprising paroxetine or physiologically acceptable salts or solvates thereof and 2-(R)-(4-Fluoro-2-methyl-phenyl)-4-(S)-((8aS)-6-oxo-hexahydro-pyrrolo[1,2-a]-pyrazin-2-yl)-piperidine-1-carboxylic acid [1-(R)-(3,5-bis-trifluoromethyl-phenyl)-ethyl]-methylamide or pharmaceutically acceptable salts or solvates thereof, to pharmaceutical compositions containing said combinations and their use in the treatment of depression and/or anxiety.
... | | S-methyl-dihydro-ziprasidone for treatment of psychiatric and ocular disorders | 20060287336 | 20061221 | | This invention relates to pharmaceutical compositions containing S-methyl-dihydro-ziprasidone and to the use of such compound and its pharmaceutically acceptable salts for the treatment of psychiatric and ocular disorders. More specifically, it relates to the use of such compound and its pharmaceutically acceptable salts for the treatment of a disorder or condition selected from: schizophrenia, anxiety disorders such as generalized anxiety disorder, panic disorder, posttraumatic stress disorder and phobias (e.g., social phobia, agoraphobia etc.); psychotic episodes of anxiety: anxiety, agitation, excessive aggression, tension, or social or emotional withdrawal associated with psychosis; psychotic mood disorders such as severe major depressive disorder; mood disorders associated with psychotic disorders such as acute mania and depression associated with bipolar disorder, and mood disorders associated with schizophrenia; behavioral disturbances associated with mental... | | Diarylmethylidene piperidine derivatives, preparations thereof and uses thereof as opoid receptors ligands | 20060287361 | 20061221 | | Compounds of general formula: (I) wherein R1, R2, R3 and A are as defined in the specification, as well as salts, enantiomers thereof and pharmaceutical compositions including the compounds are prepared. They are useful in therapy, in particular in the treatment of pain and anxiety.
... | | Vibratable, sound-emitting, and inflatable sleeping bag for providing deep pressure | 20060277680 | 20061214 | | A vibratable and sound emitting sleeping bag with an inflatable interior lining that may be inflated by the bag's occupant to provide deep pressure to the bag occupant's body when enclosed in the bag. The level of pressure applied to the individual is adjustable by a pump, adapted for control by a small child. The sleeping bag vibrates and produces sound to provide the bag's occupant with additional sensory stimulation. The sleeping bag is particularly suited for use by an autistic child for reducing the effects of autism-related anxiety and discomfort.
... | | Amines that inhibit a mammalian anandamide transporter, and methods of use thereof | 20060281742 | 20061214 | | One aspect of the present invention relates to amines. A second aspect of the present invention relates to the use of the amines as inhibitors of a mammalian anandamide transporter. The compounds of the present invention will also find use in the treatment of numerous ailments, conditions and diseases which afflict mammals, including but not limited to asthma, neuropathic pain, persistent pain, inflammatory pain, hyperactivity, hypertension, brain ischemia, Parkinson's disease, spasticity, Tourette's syndrome, schizophrenia, hemorrhagic shock, septic shock, cardiac shock, migrane, Horton's headache, multiple sclerosis, anorexia, AIDS wasting syndrome, organ rejection, autoimmune diseases, allergy, arthritis, Crohn's disease, malignant gliomas, neurodegenerative diseases, Huntington's chorea, glaucoma, nausea, anxiety, psychosis, attention deficit hyperactivity disorder, premature ejaculation, and stroke. Another aspect of the present invention relates to combinatorial libraries of... | | Method of treating an anxiety disorder | 20060281770 | 20061214 | | Anxiety disorders, such as panic disorder, agoraphobia, obsessive-compulsive disorder, social phobia, post-traumatic stress disorder, generalized anxiety disorder, specific phobia, or the like, are treated by administering an effective amount of at least one adenosine A2A receptor antagonist to a patient in need thereof, optionally in combination with an anxiolytic(s) other than the adenosine A2A receptor antagonist.
... | | Compounds having activity at 5ht2c receptor and uses thereof | 20060281786 | 20061214 | | Z is an optionally substituted N-linked heterocyclic group or a C-linked 4 to 7 membered heterocyclic group containing at least one nitrogen, or Z is —NR9R10 where R9 and R10 are independently hydrogen or C1-6alkyl. Method of preparation and uses thereof in therapy, such as for example in treatment of depression and anxiety, are also disclosed.
... | | Methods and compositions for treating neurological disorders | 20060276394 | 20061207 | | The present invention relates generally to the fields of neuroscience, growth factors and depression. More particularly, the present invention addresses the need in the art for methods and compositions for treating neurological disorders such as depression, anxiety, panic disorder, bi-polar disorder, insomnia, obsessive compulsive disorder, dysthymic disorder and schizophrenia. In certain embodiments, the invention relates to non-covalent binding interactions between insulin-like growth factors (IGFs) and IGF binding proteins (IGFBPs).
... | | Antidepressant arylpiperazine derivatives of heterocycle-fused benzodioxans | 20060276481 | 20061207 | | are useful for the treatment of depression (including but not limited to major depressive disorder, childhood depression and dysthymia), anxiety, panic disorder, post-traumatic stress disorder, premenstrual dysphoric disorder (also known as pre-menstrual syndrome), attention deficit disorder (with and without hyperactivity), obsessive-compulsive disorder, social anxiety disorder, generalized anxiety disorder, obesity, eating disorders such as anorexia nervosa and bulimia nervosa, vasomotor flushing, cocaine and alcohol addiction, sexual dysfunction and related illnesses.
... | | Substituted piperidine and piperazine derivatives as melanocortin-4 receptor modulators | 20060276485 | 20061207 | | The present invention relates to novel substituted piperidine and piperazine derivatives as melanocortin-4 receptor (MC-4R) modulators. MC-4R agonists of the invention can be used for the treatment of disorders and diseases such as obesity, diabetes, and sexual dysfunction, whereas the MC-4R antagonists are useful for the treatment of disorders and diseases such as cancer cachexia, muscle wasting, anorexia, anxiety and depression. All diseases and disorders where the regulation of the MC-4R is involved can be treated with the compounds of the invention.
... | | Exo-s-mecamylamine formulation and use in treatment | 20060276551 | 20061207 | | A pharmaceutical composition includes a therapeutically effective amount of exo-S-mecamylamine or a pharmaceutically acceptable salt thereof substantially free of exo-R-mecamylamine in combination with a pharmaceutically acceptable carrier. Preferably the amount is about 0.5 mg to about 20 mg. Medical conditions are treated by administering a therapeutically effective amount of exo-S-mecamylamine or a pharmaceutically acceptable salt thereof, substantially free of its exo-R-mecamylamine, said amount being sufficient to ameliorate the medical condition. The medical conditions include but are not limited to substance addiction (involving nicotine, cocaine, alcohol, amphetamine, opiate, other psychostimulant and a combination thereof), aiding smoking cessation, treating weight gain associated with smoking cessation, hypertension, hypertensive crisis, Tourette's Syndrome and other tremors, cancer (such as small cell lung cancer) atherogenic profile, neuropsychiatric disorders (such as bipolar disorder,... | | Functional characterization of myo-inositol monophosphatase | 20060277611 | 20061207 | | This invention relates to the functional characterization of myo-inositol monophosphatase 2 (IMPA2), one of the enzymes acting in the phosphatidyl inositol signaling pathway. In particular, the present invention provides evidence that IMPA2 is associated with depression- and anxiety inducing conditions, in particular anxiety and affective disorders. In a first aspect the present invention provides the use of an IMPA2 enzyme in an assay to identify anti-anxiety or an anti-depression compounds. In particular to the use of an isolated polynucleotide encoding said IMPA2 protein, wherein said IMPA2 protein is preferably being selected from polynucleotides encoding the mouse, rat or human IMPA2 enzyme. It is thus an object of the present invention to provide a method for identifying anti-anxiety or anti-depression compounds wherein said compounds are capable of... | | Delivery of diazepam through an inhalation route | 20060269486 | 20061130 | | The present invention relates to the delivery of compounds for the treatment of anxiety disorders and symptoms of such disorders through an inhalation route. Specifically, it relates to aerosols containing diazepam that are used in inhalation therapy. In a method aspect of the present invention, diazepam is administered to a patient through an inhalation route. The method comprises: a) heating a thin layer of diazepam on a solid support to form a vapor; and, b) passing air through the heated vapor to produce aerosol particles having less than 5% drug degradation products. In a kit aspect of the present invention, a kit for delivering diazepam through an inhalation route is provided which comprises: a) a thin coating of a diazepam composition; and, b) a device for... | | Glutamate agents in the treatment of mental disorders | 20060270647 | 20061130 | | Methods of treating mental disorders, including anxiety disorders such as obsessive-compulsive disorder, are provided. The methods comprise administering an effective amount of a glutamate modulator to an individual in need thereof. Also provided are methods of enhancing the activity of a serotonin reuptake inhibitor (SRI) comprising co-administering a glutamate modulator and a serotonin reuptake inhibitor. Pharmaceutical composition comprising a serotonin reuptake inhibitor and a glutamate modulator are also provided.
... | | Pyrazolopyrimidines as crf receptor antagonists | 20060270659 | 20061130 | | including the stereoisomers and the pharmaceutically acceptable acid addition salt forms thereof, wherein R1 is NR4R5 or OR5; R2 is C1-6alkyl, C1-6alkyloxy or C1-6alkylthio; R3 is hydrogen, C1-6alkyl, C1-6alkylsulfonyl, C1-6alkylsulfoxy or C1-6alkylthio; R4 is hydrogen, C1-6alkyl, mono- or di(C3-6cycloalkyl)methyl, C3-6cycloalkyl, C3-6alkenyl, hydroxyC1-6alkyl, C1-6alkylcarbonyloxyC1-6alkyl or C1-6alkyloxyC1-6alkyl; R5 is C1-8alkyl, mono- or di(C3-6cycloalkyl)methyl, Ar1CH2, C1-6alkyloxyC1-6alkyl, hydroxyC1-6alkyl, C3-6alkenyl, thienylmethyl, furanylmethyl, C1-6alkylthioC1-6alkyl, morpholinyl, mono- or di(C1-6alkyl)aminoC1-6alkyl, di(C1-6alkyl)amino, C1-6alkylcarbonylC1-6alkyl, C1-6alkyl substituted with imidazolyl; or a radical of formula -Alk-O—CO—Ar1; or R4 and R5 taken together with the nitrogen atom to which they are attached may form an optionally substituted pyrrolidinyl, piperidinyl, homopiperidinyl or morpholinyl group; having CRF receptor antagonistic properties; pharmaceutical compositions containing such compounds as active ingredients; methods of treating disorders related to hypersecretion of CRF such as depression, anxiety,... | | Spirocyclic heterocyclic derivatives and methods of their use | 20060270695 | 20061130 | | Spirocyclic heterocyclic derivatives, pharmaceutical compositions containing these compounds, and methods for their pharmaceutical use are disclosed. In certain embodiments, the spirocyclic heterocyclic derivatives are ligands of the δ opioid receptor and may be useful, inter alia, for treating and/or preventing pain, anxiety, gastrointestinal disorders, and other δ opioid receptor-mediated conditions.
... | | Scopolamine for the treatment of depression and anxiety | 20060270698 | 20061130 | | Provided herein are methods and compositions for the treatment of depression and anxiety. The compositions comprise scopolamine, or an analog thereof, and can optionally include one or more psychoactive agents. Further provided is an inhaler comprising scopolamine, or an analog thereof, in a pharmaceutically acceptable carrier.
... | | Apparatus for pediatric resuscitation | 20060270914 | 20061130 | | A medical apparatus is described that simplifies decision-making at the time of pediatric resuscitation by measuring the patient's weight while laying in the medical apparatus and using that information to reduce the need to estimate the quantity or size of a child's required interventions, thereby reducing the need for multiple calculations at a time of anxiety.
... | | 6-(2,2,2-trifluoroethylamino-7-chloro-2,3,4,5-tetrahydro-1h-benzo[d] azephine as a 5-ht2c receptor agonist | 20060264418 | 20061123 | | The present invention provides a 7-chloro-6-(2,2,2-trifluoroethylamino)-2,3,4,5-tetrahydro-1H-benzo[d]azepine of formula (I): or a pharmaceutically acceptable salt thereof, and its use as a selective 5-HT2c agonist for the treatment of 5-HT2c associated disorders including obesity, obsessive/compulsive disorder, anxiety, and depression.
... | | Benzoxazinone derivatives, preparation thereof and uses in the treatment of cns and other disorders | 20060264429 | 20061123 | | wherein A, R1, R2, R3, p, q, A and X are as defined in the specification. Preparation of the compounds and uses in the treatment of CNS and other disorders, including depression and anxiety, are also disclosed.
... | | Azabicyclylmethyl derivatives of 2,3-dihydro-1,4-dioxino [2,3-f]quinoline as 5-ht1a antagonists | 20060264437 | 20061123 | | are useful for treating the cognitive deficits due to aging, stroke, head trauma, Alzheimer's disease or other neurodegenerative diseases, or schizophrenia, and are also useful for the treatment of disorders such as anxiety, aggression and stress, and for the control of various physiological phenomena, such eating disorders, disorders of thermoregulation, and sleep and sexual dysfunction.
... | | Bridged ring nk1 antagonists | 20060258665 | 20061116 | | or pharmaceutically acceptable salts and/or solvates thereof are useful in treating diseases or conditions mediated by NK1 receptors, for example various physiological disorders, symptoms or diseases, including emesis, depression, anxiety and cough.
... |
Other Directories (alphabetical): , , , , , , , , , , , , , , , , , , , , -
###
This listing is a sample listing of patents related to Anxiety for is only meant as a recent sample of applications filed, not a comprehensive history. There may be associated servicemarks and trademarks related to these patents. Please check with patent attorney if you need further assistance or plan to use for business purposes. This patent data is also published to the public by the USPTO and available for free on their website. Note that there may be alternative spellings for Anxiety with additional patents listed. Browse our RSS directory or Search for other possible listings.
|
